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Ovarian cancer affects 1 in 70 women in developed countries and is the leading
cause of death from gynaecological malignancies. Ninety percent of ovarian
tumours are of epithelial origin. Serous cystadenocarcinoma is the most prevalent of
these tumours, constituting 60% of epithelial ovarian cancers. Although, clinical
and pathological features of ovarian tumours are currently used to predict the course
of disease, there is a need to identify molecular markers that could reliably predict
the clinical outcome of patients. Dysregulation of cell cycle control, in particular Gi
to S phase transition, has been implicated in the pathogenesis of many human
cancers. Recent studies of molecular markers and clinical outcome in ovarian
cancer, have identified several cell cycle regulatory genes that may be important in
disease progression that include p53, p21 afl/Cipl and p27Kipl, although the results
are far from conclusive.
In this study the relationship between the expression of p53, p21Wafl/Cipl, p27Kipl,
pjgink4a^ CyCims qj and E, and pRb with disease outcome and other
clinicopathological characteristics of serous epithelial ovarian cancer was sought.
Molecular markers predictive of reduced disease-specific survival (DSS) in the
cohort included overexpression of cyclin D1 (p=0.03) and p53 (p=0.02), reduced
expression of p27Icipl (p=0.05) and loss of p21 afl/Cipl (p=0.02), with the latter three
being prognostic for a shorter progression-free interval (PFI). When various
combinations of p53 and p21Wa 1/Cipl expression were analysed, patients whose
tumours displayed overexpression of p53 with concurrent loss of p2iWafl/CipI had a
significantly shorter DSS (p=0.0008) and PFI (0.0001) than patients with other
combinations of these two molecules. On multivariate analysis overexpression of
cyclin D1 and combined loss of p2iWafl/Cipl in the presence of p53 overexpression
were independent predictors of DSS when adjusted for volume of residual disease,
presence of ascites and performance status. Similarly, loss of p2iWafl/Cipl jn the
presence of p53 overexpression was independently predictive of a shorter PFI when
considered with residual disease, performance status and ascites. Overexpression of
cyclin E and p53, reduced expression of p27Kipl, and loss of p2iWal/Cipl were
associated with increasing tumour grade. Expression of pRb, pi6 4a and cyclin E
were not associated with clinical outcome. A more detailed analysis of p53 staining
in this cohort of tumours revealed a bimodal distribution of p53 expression.
Survival analysis of subgroups of patients when stratified for p53 expression,
demonstrated that p53 expression of >5% and <50% was associated with a
significantly reduced 5-year DSS (p<0.0001) and PFI (<0.0001), in contrast to
patients with tumours displaying p53 expression of <5% or >50%.
In conclusion, cyclin D1 overexpression was associated with poor clinical outcome.
Overexpression of p53 with concurrent loss of p21Wafl/c,pl was a stronger prognostic
marker of disease outcome than expression of either molecule alone and may be of
clinical utility in treating patients with serous ovarian cancer.
Ill
Acknowledgements
The studies in this thesis were completed at the Garvan Institute of Medical
Research, St. Vincent's Hospital Sydney. The project was designed in collaboration
with the Gynaecology Cancer Centre, Royal Hospital for Women, Sydney.
Firstly, I would to thank Dr. Raphe Robinson, now retired Gynaecology Oncologist,
with whom I had the immense pleasure of working with at Addenbrooke's Hospital,
Cambridge, UK. Dr. Robinson initially planted the seed and "got the ball rolling"
that eventuated in me coming to Australia to pursue research in gynaecology
oncology. However, this would not have been possible without the initial help and
subsequently on-going encouragement and advice from Professor Neville Hacker,
Gynaecology Oncologist at the Royal Hospital for Women, and to whom I am
extremely indebted. In addition, I am grateful to the Gynaecology Oncology
Foundation for their scholarship. I am also very grateful to Professor Rob
Sutherland for providing me with the opportunity to work within the Cancer
Research Program at the Garvan Institute. It has been a truly memorable experience.
Within the Translational Research Group, I would like to extend my thanks to
several people for their friendship, advice and assistance. Over the past two years, it
has been a great pleasure to work with David Quinn, Kim Bonner, Lisa Hovarth,
Kris Rasiah, Rhonda Kwong, Rebecca Walsh, Luis Winoto, Guillermo Ruggeri,
Nicole Sly, Darren Head and more recently Patricia Vanden Bergh and Margeret
Garden-Gardiner. A very special thanks to Andrew Biankin for not only his
frequent distractions and special views on the "meaning of life", but more seriously
for assisting in and often resolving various recurring computer frustrations. I am
also extremely grateful to Susan Henshall for always providing me with practical
advice and help concerning many aspects of this project, but moreover for her on¬
going support and friendship over these two years.
I would also like to thank Lyndal Edwards, for her enthusiasm and patience in
guiding me and contributing to the pathological aspects of this project.
Finally, I would like to thank my mother and father for their continuing
understanding, love and often advice during these two years, and my brother and






List of Figures VII
List of Tables IX
Abbreviations XI
Chapter One Clinical aspects of ovarian cancer
1.1 Introduction 1
1.2 Epidemiology and risk factors 2
1.2.1 Epidemiology 2
1.2.2 Risk factors: Sporadic ovarian cancer 4
1.2.3 Risk factors: Hereditary ovarian cancer 5
1.3 Pathology 6
1.4 Clinical prognostic markers determining disease outcome of patients
with ovarian cancer 11
1.5 Clinical management of patients with ovarian cancer 14
1.5.1 Screening 14
1.5.2 Surgery 16
1.5.3 Chemotherapy and Radiotherapy 17
1.5.4 Gene therapy 19
1.6 Conclusion 20
Chapter Two Molecular genetics of ovarian cancer
2.1 Introduction 21
2.2 Cell cycle regulation 25
2.3 Aberrant expression of specific cell cycle genes in epithelial ovarian
cancer 32
2.3.1 p53 33
2.3.2 Cyclin Dependent Kinase Inhibitors: p2iWaf1Cip1, p27Kip1 and
p16lnk4a 35
V
2.3.3 Cyclins: Cyclin D1, Cyclin E 37
2.3.4 pRb 40
2.4 Conclusion and Aims of Thesis 41
Chapter Three Materials and Methods





3.2.4 p27Kip1, p16lnk4a, Cyclin E 47






4.2 Characteristics of study cohort: Clinicopathological determinants of
disease outcome 56
4.3 Cell cycle gene expression in ovarian cancer: correlation between
patterns of gene expression and clinicopathological characteristics. 57
4.3.1 Clinicopathological and molecular correlates of p53
expression 58
4.3.2 Clinicopathological and molecular correlates of p2iWa,1<Cip1
expression 61
4.3.3 Clinicopathological and molecular correlates of p27Kip1
expression 64
4.3.4 Clinicopathological and molecular correlates of cyclin D1
expression 67
4.3.5 Clinicopathological and molecular correlates of cyclin E
expression 70
4.3.6 Clinicopathological and molecular correlates of pRb
expression 73
VI
4.3.7 Clinicopathological and molecular correlates of p16lnk4a
expression 76
4.4 Association between cell cycle gene expression, disease-specific
survival and progression-free interval 79




5.2 p53 and p2iWaf1iCip1 expression in serous epithelial ovarian cancer... 89
5.3 Cyclin D1 /p16lnk4a/pRb expression in serous epithelial ovarian
cancer 93






Figure 1.1 Incidence and mortality rates for ovarian cancer in Australia... 3
Figure 1.2 Schematic representation of FIGO clinical staging of epithelial
ovarian cancer 10
Chapter Two
Figure 2.1 Schematic illustration of G, to S phase transition in the
mammalian cell cycle 26
Chapter Three
Figure 3.1 Expression of p53, p2lWa,1iCip1, p27Kip1, cyclin D1, cyclin E, pRb,
and p16lnk4a in cell line controls 51
Chapter Four
Figure 4.1 p53 expression in serous epithelial ovarian cancer 60
Figure 4.2 p21Waf1/Cip1 expression in serous epithelial ovarian cancer 63
Figure 4.3 p27Kip1 expression in serous epithelial ovarian cancer 66
Figure 4.4 Cyclin D1 expression in serous epithelial ovarian cancer 69
Figure 4.5 Cyclin E expression in serous epithelial ovarian cancer 72
Figure 4.6 pRb expression in serous epithelial ovarian cancer 75
Figure 4.7 p16lnk4a expression in serous epithelial ovarian cancer 78
Figure 4.8 Kaplan-Meier curves of DSS according to p53 and p21Wa,1/Cip1
expression 81
VIII
Figure 4.9 Kaplan-Meier curves of PFI according to p53 and p21Wa,1iCip1
expression 80
Figure 4.10 distribution of p53 expression in tumour cohort 82
Figure 4.11 Stratification of p53 expression and association with disease-
specific and progression-free survival 85
Chapter 5
Figure 5.1 Aberrant expression of and interaction between cell cycle




Table 1.1 Five-year survival rates of epithelial ovarian cancer by FIGO
stage 3
Table 1.2 International Federation of Gynaecology and Obstetrics (FIGO)
staging system for ovarian cancer 9
Chapter Two
Table 2.1 Common genetic mutations identified in ovarian cancer 22
Table 2.2 Literature review of p53 alteration and clinical outcome in ovarian
cancer 33
Table 2.3 Literature review of aberrant p2iWa,1/Cip1 expression and clinical
outcome in ovarian cancer 36
Table 2.4 Literature review of cyclin D1 expression and clinical outcome in
ovarian cancer 39
Chapter Three
Table 3.1 Clinical and pathological characteristics of patient 44
Table 3.2 Anti-p53 antibody and cell line controls 46
Table 3.3 Anti-pRb antibody and cell line controls 46
Table 3.4 Anti-p21Wa,1/Cip1 antibody and cell line controls 47
Table 3.5 Anti-p27Kip1 antibody and cell line controls 48
Table 3.6 Anti-pie^1 antibody and cell line controls 48
Table 3.7 Anti-cyclin E antibody and cell line controls 48
Table 3.8 Anti-cyclin D1 antibody and cell line controls 49
Table 3.9 Cut-off values for positive antigen staining 52
X
Chapter Four
Table 4.1 Univariate analysis of relationships between clinicopathological
characteristics and disease-specific and progression-free survival
57
Table 4.2 Immunohistochemistry of cell cycle genes in serous epithelial
ovarian cancer 58
Table 4.3 Correlation between p53 expression and clinicopathological and
molecular parameters 59
Table 4.4 Correlation between p21 Waf1/c'P1 expression and
clinicopathological and molecular parameters 62
Table 4.5 Correlation between p27Kip1 expression and clinicopathological
and molecular parameters 65
Table 4.6 Correlation between cyclin D1 expression and clinicopathological
and molecular parameters 67
Table 4.7 Correlation between cyclin E expression and clinicopathological
and molecular parameters 70
Table 4.8 Correlation between pRb expression and clinicopathological and
molecular parameters 73
Table 4.9 Correlation between p16lnk4a expression and clinicopathological
and molecular parameters 76
Table 4.10 Univariate analysis of molecular markers to disease-specific
survival and progression-free interval 80
Table 4.11a Multivariate Cox regression analysis of overall disease-specific
survival 86
Table 4.11 b Multivariate Cox regression analysis of progression-free interval
86
Abbreviations
95% Cis 95% confidence intervals
BSA bovine serum albumin
B brenner
CC clear cell
CDK cyclin dependent kinase
CDKI cyclin dependent kinase inhibitor
DNA deoxyribonucleic acid
DSS disease specific survival
E endometrioid
EOC epithelial ovarian cancer
FIGO International federation of gynaecology and obstetrics
G1 gap 1 phase of the cell cycle
G2 gap s phase of the cell cycle









NHS normal horse serum
NS not specified
PFI progression free interval
PLAP placental alkaline phosphatase
PS performance status
PBS phosphate buffered saline
pRb retinoblastoma protein
p16lnk4a-- 16 kDa cyclin dependent kinase inhibitor
p2i wafi/ciPi 21 kDa cyclin dependent kinase inhibitor
p27K'pi 27 kDa cyclin dependent kinase inhibitor





S phase DNA synthesis phase of the cell cycle
TBS tris buffered saline
U undifferentiated
WHO world health organisation
X chromosome
Chapter One Clinical aspects of ovarian cancer
1.1 Introduction
Ovarian cancer affects one in seventy women in developed countries, and is the fifth
leading cause of cancer-related mortality amongst women (1). Typically this cancer
has an insidious onset and over 70% of women present with advanced disease that
has spread beyond the ovary. In this population, 5-year survival is 25% despite
optimal surgery and aggressive chemotherapy (2).
Treatment for ovarian cancer was first reported in 1586, and by the late 19th century
surgical removal of the diseased organ had become accepted practice (3). In addition
to the various modifications of surgical practice, the past 30 years have seen the
emergence of chemotherapy and radiotherapy as powerful adjuvant tools in the
treatment of cancerper se.
With an emphasis on centralisation of cancer services and recruitment of patients on
well-constructed clinical trials, significant inroads are being made to improve the
overall and palliative outcome of patients with ovarian cancer. In addition, a more
comprehensive understanding of cancer aetiology is essential to achieve significant
advances in the treatment of this disease, and the past decade has seen a flourish of
activity in the fields of cancer genetics and molecular biology.
The primary aim of this thesis is to identify a pattern of gene expression in the
development of ovarian cancer, which correlates with an aggressive phenotype, and
identify biomarkers of clinical utility and therapeutic importance in ovarian cancer.
In order to do this it is necessary to review the genetic factors that may predict cancer
development and progression, as well as clinicopathological parameters that
influence disease outcome once diagnosed. Many tumour types have been identified
to involve the ovary, and this thesis concentrates primarily on serous
cystadenocarcinomas.
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1.2 Clinical epidemiology and risk factors of ovarian cancer
1.2.1 Epidemiology
Ovarian cancer is the leading cause of death from gynaecological malignancies in the
western world (4). In 1997, the Australia Cancer Society reported 1151 new cases of
ovarian cancer and 740 deaths. This translates to an annual incidence of 11.0 per
100,000 population, and a mortality rate of 6.8 per 100,000 population (5). In
Australia there has been no significant change in the incidence of, and mortality rates
from ovarian cancer since 1983 (6), (Figure 1.1). The peak incidence of invasive
malignancy is in the sixth decade, with the age-specific incidence rising precipitously
from 20 to 80 years and subsequently declining (5). The clinical outcome of patients
diagnosed with this disease is poor. In over two-thirds of women, presentation is
generally delayed and advanced disease diagnosed due to the absence of early signs
and symptoms, and a lack of effective screening tests for diagnosing early disease
(7). Consequently, the 5-year survival in this group of patients with advanced
disease is 25%. Table 1.1 illustrates the distribution and approximate 5-year survival
of women diagnosed with epithelial ovarian cancer in developed countries.
Distribution of the disease among patients is based on a standardised staging system
introduced by the International Federation of Gynaecology and Obstetrics (8). The
staging system is discussed in more detail in section 1.3, but in essence, separates
women depending upon the spread of the disease at presentation. Treatment of
ovarian cancer relies on radical surgery and aggressive cytotoxic chemotherapy, but
despite all efforts, the cancer continues to progress rapidly in 15% of patients, and a
further 50% suffer relapse within 2 years of their initial treatment.
Ninety to ninety-five percent of ovarian cancer is sporadic in nature, with the
remainder being familial (9). Of those sporadic cases, 90% are defined as Epithelial
Ovarian Cancers (EOC), denoting their origin from the surface epithelium of the
ovary or from its corresponding invaginations into the ovarian stroma (10).
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Figure 1.1 Incidence and mortality rates for ovarian cancer in Australia




Table 1.1 Five-year survival rates of epithelial ovarian cancer by
FIGO stage (Adapted from reference 7)
Stage Comment (abbreviated) Distribution 5-year
(% population) Survival (%)




II Confined to pelvis 13 57
IIA 3 61
I IB/I IC 10 56




IV Metastases elsewhere 16 8
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1.2.2 Risk factors: Sporadic ovarian cancer
The aetiology of sporadic ovarian cancer is unknown. However, epidemiological
studies identify numerous factors that may influence the risk of developing ovarian
cancer (2, 11-19). The number of ovulatory cycles in a woman's reproductive
lifetime is the most significant of these associations, giving rise to the "incessant
ovulation" hypothesis (20). Theoretically, the repetitive disruption and repair of the
surface epithelium of the ovary during ovulation may lead to spontaneous genetic
mutations that in turn may confer an oncogenic phenotype to the epithelial cells.
Consequently, reducing the number of ovulatory cycles may result in a decreased
risk of developing this disease. Use of the oral contraceptive pill is associated with
up to a 70% reduction of developing EOC after 10 years or more of use compared
with no-use (11, 12). In addition, multiparity, breast feeding, late menarche and early
menopause, that are all associated with reducing the number of ovulations, have been
shown to confer a protective effect in developing EOC (13, 15).
Although several other factors have been thought to influence the risk of developing
EOC, the findings have generally been inconclusive. The associated risk with the
use of perineal talcum powder and EOC has been investigated and remains
controversial (21-23). The initial impetus to study this substance was its chemical
similarities to asbestos and frequent use of talc around the perineum (24). Asbestos
was shown to cause ovarian epithelial hyperplasia in animal experiments,
comparable to changes seen in early EOC in patients (24). Heller and colleagues
demonstrated retrograde deposition of talc particulates on the ovary through the
reproductive tract, although subsequent studies failed to conclusively prove its role
as a risk factor for EOC (23, 25, 26). Partly within the same paradigm of retrograde
peritoneal exposure to carcinogenic agents, the effect of tubal sterilisation and
hysterectomy has been investigated. Green and colleagues reported a significant
reduction in the risk of developing EOC by 39% after tubal occlusion and by 36%
after hysterectomy in a sample population of Australian women (16). However,
surgical interruption of the utero-ovarian circulation results in fewer ovulations, and
this may be accountable for the protective effect against EOC (27).
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The effects of infertility and use of fertility drugs with in-vitro fertilisation have also
been studied (18, 28-31). There is no conclusive evidence that transient use of
fertility drugs influence the risk of EOC although, unexplained infertility per se may
be associated with an increased risk over and beyond that in nulliparous women.
The reason for this is unclear. More recently, epidemiological data suggest a 2-fold
increase in the risk of developing EOC with prolonged use of oestrogen replacement
therapy in the menopause (17, 32). One possible mechanism accounting for this
increased risk is the direct effect of oestrogen on epithelial ovarian cells. In cell line
experiments exposure to oestrogen results in a rapid increase in proliferation of
ovarian cancer cells (33, 34). In addition, tamoxifen, an anti-oestrogen, has been
reported to have beneficial effects in a few women with ovarian cancer (35).
1.2.3 Risk factors: Hereditary ovarian cancer
Although the lifetime risk of a woman developing ovarian cancer in developed
countries is 1 in 70, a strong family history of either breast or ovarian cancer
increases this risk substantially (36, 37). Hereditary ovarian cancer is uncommon,
and accounts for 5-10% of all ovarian tumours. Although the factors mentioned
above are thought to influence the risk of developing EOC in these women, germline
mutations in the BRCA1 and BRCA2 breast/ovarian susceptibility genes
overwhelmingly account for most hereditary cancers. In families with BRCA1 and
BRCA2 mutations, the lifetime risk of developing ovarian cancer is 60% and 30%
respectively (9, 38-40). However, the accuracy of this risk is debatable as the bias of
most surgeons is to recommend bilateral oophorectomy in this population once child
bearing is complete (9, 41). Although the risk is not completely negated with this
procedure, it is considerably reduced (42). However, oophorectomy is not a
reasonable option in young women wishing to retain their fertility. Epidemiological
data from the Gilda Radner Familial Ovarian Cancer Registry show that oral
contraceptive use is associated with a lower risk of developing ovarian cancer in
BRCA1 and BRCA2 carriers (43). In conjunction with intensive screening, oral
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contraceptives might be an attractive alternative in women who have not completed
childbearing.
1.3 Pathology
Histology of the normal ovary is complex. During embryonic life a gonadal ridge is
formed by a thickening of coelemic epithelium, which forms the serosal covering of
the ovary. This epithelium, by a process of invagination, gives rise to the mullerian
ducts from which the fallopian tubes, uterus and upper vagina form. The outer
epithelial layer, or serosa, surrounds a dense stromal mass that contains arrested
primary oocytes, developing primary and secondary follicles, a corpus luteum, and
lymphatic and vascular drainage (8). All cellular subtypes are prone to cancerous
transformation, and cancer of the ovary can be broadly categorised as epithelial,
germ cell or stromal in origin. Ninety percent of all ovarian tumours are epithelial in
nature, and consequent to common origins of the ovarian surface mesothelium and
epithelium of the mullerian ducts, EOC can develop along 5 routes (8, 44). Serous
cystadenocarcinomas are by far the most common, accounting for 60% of EOC's.
They present as bilateral tumours in 50% of cases, and have a multiloculated, cystic
appearance on gross pathology. They are composed of low columnar epithelial cells
that morphologically resemble the epithelial cells of the fallopian tube mucosa.
These cells lack intra-cellular mucin, and grow in a papillary histological pattern
(44).
The remainder of EOC's consist of mucinous, endometrioid, clear cell and Brenner
tumours. Mucinous cancers are composed of columnar cells that resemble
endocervical epithelial cells, and contain abundant cytoplasmic mucin. These
tumours comprise 10-20% of EOC's and present bilaterally in a quarter of cases.
Endometrioid ovarian cancer, which account for 10-20% of EOC's, typically
resembles endometrial tumours of the uterus. The corresponding cells are columnar
with elongated dark nuclei, and grow in a tubular or cribriform pattern. Clear cell
carcinomas are rare and comprise 3% of EOC's. They are composed of cells laden
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with glycogen that are similar to glandular endometrial cells associated with
pregnancy. Brenner tumours are composed of transitional cells, and are identical to
tumours of the urinary tract. They account for less than 2% of EOC's and are
typically unilateral on presentation (8, 44, 45).
The debate on precursor lesions resultant in invasive EOC, analogous to cervical
intra-epithelial neoplasia progressing to invasive cancer (46), remains unresolved
(10, 47, 48). Cellular atypia and metaplastic change on the surface epithelium of the
ovary and of the epithelial lining of inclusion cysts adjacent to invasive neoplasia has
been reported (49). However, it is rare to find these changes in the absence of
invasive cancer (10). A further interesting observation is that cortical inclusion cysts
are found in increased numbers in apparently normal ovaries contralateral to ovarian
cancer, compared to ovaries from age-matched women without ovarian cancer (50).
Whether this increased frequency represents a requirement for the development of
EOC is questionable. There also remains intense debate about the nature of
borderline tumours of Low Malignant Potential (LMP). Initially thought to be
precursors of their invasive counterparts there is mounting evidence for their
classification as a unique entity (51-55). Borderline tumours share similar histology
patterns to their malignant counterparts, are able to metastasise in a transcoelemic
fashion, but lack important invasive properties. Consequently, patient survival over
5 years is in the order of 95%, despite having apparently advanced disease (55). It is
also rare to find foci of borderline tumours in otherwise frankly malignant tissue
(10). In addition, recurrent borderline tumours are characteristically identical to that
of the original lesion and do not appear to progress to invasive malignancies. There
is also limited evidence of genetic dissimilarities between the 2 tumour subtypes.
For example, p53 gene mutation and mutant protein overexpression is found in over
50% of invasive EOC, but rarely occurs in the borderline variant (52, 54).
Therefore, the histological classification of ovarian tumours reflects both the cell
type and the biological behaviour of that tumour. The degree of cellular
differentiation, nuclear atypia, and loss of architectural integrity, are summarised in a
grading system that provides additional information on the behaviour of tumour
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subtypes (8). In general, well differentiated tumours more closely resemble their
normal counterparts, with poorly differentiated tumours at the other extreme.
Defining the cellular origin and grade of the cancer is important, because of
correlation with prognosis and occasional therapeutic implications. In addition,
some pathologists report the mitotic activity index of the tumour, degree of DNA
ploidy and percentage of surface epithelium involved in carcinomatous change, as
these factors have shown to have some prognostic influence on disease outcome (56-
58). However, these factors are weak prognosticators of clinical outcome and are
generally not reported.
Invasive EOC metastasise in three ways. The earliest route of dissemination is
transcoelemic, with exfoliated cells implanting along the surfaces of the peritoneal
cavity. Spread via the lymphatic system, is mainly along the nodal chain in the
pelvis, to the para-aortic region at the level of the renal vessels. These nodes are
involved in 15 to 20 percent of stage I and II cases, and up to 50 percent in the latter
stages. Haematogenous spread is rare and occurs late. The main sites of distant
metastases are the liver and lungs, although spread to bone and brain is sometimes
seen (7). The extent of metastatic spread is incorporated in the FIGO clinical staging
process for this disease that is summarised in Table 1.2 and illustrated in Figure 1.2.
This consensus standardisation by the International Federation ofGynaecologists and
Obstetricians is vital, as it not only dictates the therapeutic options available to the
clinician and patient, but is also an important prognostic factor in determining overall
and progression-free survival of patients.
Table 1.2 International Federation of Gynaecology and Obstetrics
(FIGO) staging system for ovarian cancer*
Stage I Growth limited to the ovaries
la Growth limited to one ovary, no malignant cells in ascitic fluid
or peritoneal washing; No tumour on the external surface;
capsule intact.
lb Growth limited to both ovaries, capsule intact, no malignant
cells in ascitic fluid or peritoneal washings; No tumour on the
external surface; capsule intact.
Ic As with la or lb but with tumour on the surface of one or both
ovaries; or with capsule ruptured; or with malignant cells in
ascitic fluid or positive peritoneal washings.
Stage II Growth involving one or both ovaries with pelvic extension
lla Extension and/or metastases to the uterus and/or tubes. No
malignant cells in ascitic fluid or peritoneal washings,
lib Extension to other pelvic tissues. No malignant cells in
ascitic fluid or peritoneal washings
lie As in lla or lib but with tumour on the surface of one or both
ovaries; or with capsule(s) ruptured; or with malignant cells
in ascites or peritoneal washings
Stage III Tumour involving one or both ovaries with peritoneal
implants outside the pelvis and/or positive retroperitoneal or
inguinal lymph nodes. Superficial liver metastases equals
stage III. Tumour is limited to the true pelvis, but with
histologically proven malignant extension to small bowel or
omentum.
Ilia Tumour grossly limited to true pelvis with negative nodes but
histologically confirmed microscopic seeding of abdominal
peritoneal surfaces
11 lb Tumour of one or both ovaries with histologically confirmed
implants of abdominal peritoneal surfaces, none exceeding 2
cm in diameter. Nodes negative
lllc Abdominal implants > 2cm in greatest dimension
and/or retroperitoneal or inguinal nodes
Stage IV Growth involving one or both ovaries with distant
metastases. If pleural effusion is present, their must positive
cytologic test result to allot a case to stage IV. Parenchymal
liver metastases equals stage IV.
*(From: Atlas of Tumour Pathology, 3rd series, eds. AFIP, Scully RE,
Young RH, Clement PB.)
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1.4 Clinical prognostic markers determining disease outcome of
patients with ovarian cancer
"A prognostic indicator is a factor defined at a given time point which gives
information on the subsequent clinical outcome (of a patient)", Eisenhauer, 1999
(59). Numerous clinicopathological variables have been evaluated that impact on the
overall and disease free survival of patients with ovarian cancer (57-76). These
include clinical stage; volume of post-operative residual disease; histological grade
including mitotic index, DNA ploidy and cell type; presence of preoperative ascites;
age and performance status of the patient and pre-treatment and intra-treatment
levels of serum CA125. While most factors in various settings have been shown to
be independent predictors of survival, the most important remain clinical stage and
residual disease (60-67).
Clinical stage is determined at the time of primary surgery, using the FIGO staging
system, which is summarised in Table 1.2. In general, patients with cancer confined
to the ovary or pelvis, as in stages I and II, do considerably better than those in
whom the cancer has metastasised beyond the pelvis. In most series, the prognostic
influence of stage and substage remains significant even when other factors are
considered in a multivariate assessment of disease outcome (62, 63). The role of
maximal cytoreductive surgery in patients with ovarian cancer was first established
in 1968 (68). Since then numerous studies have confirmed a better progression-free
and overall survival of patients in whom there was minimal residual disease (RD)
remaining after primary surgery (60, 61, 64, 66). The "minimal" now generally
accepted is RD of less than 2cm as the maximal diameter of the largest remaining
deposit of cancer. Adding weight to the argument for optimal debulking, is the
conceptual theory that chemotherapy is more effectively delivered to smaller volume
disease. Approximately 70% of patients present with advanced disease in whom
survival is generally poor. The role of optimal debulking in this population is of vital
importance. Even in those patients with hepatic metastases and/or malignant pleural
effusions, Naik et al., (2000) (66) and Munkarah el al., (1997), (65) respectively,
demonstrated that the volume of post-operative RD is an important determinant of
prognosis. More recently, Akahira and colleagues (2001) reported a survival
advantage of 16 months in those patients with stage IV disease that were optimally
debulked (69).
EOC, as mentioned previously, cluster into 5 different subtypes dependent upon their
cell type. For any given stage, or volume of RD, clear cell carcinomas have the
worst overall prognosis and endometrioid tumours have the best (8). In addition to
their distinct morphologic appearance, there is increasing molecular evidence for
their heterogeneity. In a recent publication, Ono et al., (2000), used DNA
microarray technology to examine the expression of 9121 genes in 4 serous and 5
mucinous ovarian cancers (70). Whilst they demonstrated differential up and down-
regulation of 55 and 48 genes in all 9 cancer specimens versus normal ovary, they
identified 115 genes that were differentially expressed between serous and mucinous
tumours. This raises an interesting biological question of whether tumours of
varying cellular subtypes should be grouped as a single entity for the purpose of
molecular and clinical research, as it is frequently done in the case ofEOC's.
The degree of tumour differentiation relates to the extent of cellular and nuclear
atypia and architectural disruption of the organ. Most studies group the moderately
and poorly differentiated tumours together as these have been shown to directly
correlate with adverse prognosis in patients relative to those with well-differentiated
cancers (71-73), In a similar vein, the importance ofDNA ploidy (aneuploid versus
diploid) in tumour specimens in predicting survival has also been investigated (71,
73-76). Only two studies appear to support its independent role in multivariate
analysis when adjusted for other prognosticators (71, 75). However, this predictive
role appears to co-segregate with early stage tumours and thus may be an important
factor in distinguishing patients that have a better outcome in this population (75).
Intra-abdominal ascites is present in up to 40% of women diagnosed with ovarian
cancer. Fluid accumulates as a result of lymphatic obstruction and increased
secretion from the peritoneal surfaces. The ensuing electrolyte imbalance influences
the patients' ability to tolerate treatment. The presence of pre-operative ascites has
been shown to be associated with poor survival in patients with ovarian cancer (60,
77-79). Puis et al., (1996), reported a 5-year survival of 45% in patients with stage
III disease without ascites, versus 5% survival in a comparative group with ascites
(79).
The Performance Status (PS) is a measure of the severity of symptoms suffered by an
individual as a consequence of their disease. In general these physical
manifestations of the disease are quantified in a scoring system dependent upon
which system is used. Several systems exist which include Kranofsky scales, WHO
and GOG. The most convincing role of PS as a prognosticator of disease outcome
was shown by Warwick et al., (1995), in the long-term follow up of 362 patients
diagnosed with advanced ovarian cancer between 1981 and 1991 in the West
Midlands, UK (73). In their multivariate model, PS was the strongest predictor of
survival above RD and serum albumin levels (73). Although other groups have been
unable to attribute such importance to PS, their results generally support the
independent prognostic value for this marker (80, 81). However, the issue of ageper
se as a prognostic indicator is difficult to evaluate. In a study of 12,316 women with
ovarian cancer, Hightower et al., (1994), reported that women over the age of 80 did
considerably worse than younger patients (82). However, it was noted that those
patients over the age of 80 underwent less aggressive surgery and were generally
offered less cytotoxic chemotherapy. This did not reflect the performance status of
the patient, but related more to the belief of the treating physician that older patients
may not be able to tolerate the radical procedures required in order to effectively
treat their ovarian cancer.
1.5 Clinical management of patients with ovarian cancer
Within the paradigm of cancer treatment, centralisation of services is crucial. A
multidisciplinary approach to such management in specialist centres is mandate and
preliminary results show improved survival of patients treated under such conditions
(83, 84). It also provides the platform for patient recruitment in stringent clinical
trials involving modified or new treatments.
1.5.1 Screening
In the overall management of ovarian cancer, screening for the detection of early
disease must play a pivotal role. However, while significant inroads are being made
in screening for hereditary ovarian cancer (9, 36, 85-87), effective tests in screening
for sporadic tumours, that constitute over 90% of all ovarian cancers, remain elusive.
Ideally, a screening test should have complete sensitivity to detect all positive cases,
and sufficient specificity to rule out all negatives ones. In the past 15 years, an
enormous amount of research has been dedicated to evaluating the role of pelvic
ultrasonography and serum CA125 levels as potential screening tools for ovarian
cancer (87-102).
In 1983, Bast and colleagues were the first to report the use of CA125 measurement
in monitoring the course of patients with EOC (88). This large glycoprotein is
secreted by the endothelial cells of most pelvic organs including normal ovary, and
by mesothelial cells of pleura, pericardium and peritoneum. Levels are elevated in
1% of the normal population, 6% of patients with benign disease such as
endometriosis and pleuritis, 28% of patients with non-gynaecological intra¬
abdominal malignancies, and 60% of patients with EOC (89, 90). CA125 serum
levels are only elevated in 50% of patients with early stage EOC (91) and therefore
the solitary use of CA125 as a screening tool for the early detection of EOC suffers
from poor specificity and sensitivity. However, there is now considerable evidence to
support the use of CA125 as a marker of response to therapy and as an indicator of
relapse during follow-up (92, 93). In 70% of patients a rising CA125 titre is a first
indication of relapse, predating clinical relapse by a median of 4 months. While this
may be useful in initiating treatment sooner, a clearer benefit of earlier detection in
improving survival has not been clearly demonstrated (90). Moreover, the earlier
introduction of chemotherapy must be weighed against the loss of treatment free
time, anxiety and repeated hospital visits, as relapse is usually incurable.
Nevertheless, CA125 measurement in predicting relapse has been universally
adopted. Similarly, it is a useful marker in predicting progressive disease and
treatment failure (90, 94). Adjuvant therapy can be tailored for such patients as to
avoid the toxic side effects of treatment if unnecessary, thereby temporarily
improving their quality of life.
With an improvement in radiological techniques in the past decade, the use of real¬
time ultrasonography and colour flow doppler in detecting early EOC has been
evaluated (95-98). In the largest study to date, Jacobs et al., (1993) investigated the
efficacy of regularly screening 22,000 postmenopausal volunteers using pelvic
ultrasound in conjunction with serum CA125. Forty-one women underwent
operations following abnormal results, in whom 11 cancers were discovered. There
were altogether 19 ovarian cancers in the group of 22,000 women tested. The results
were generally disappointing with the screening modalities having a positive
predictive value of 20% and a poor sensitivity (91). These results are in concordance
with other published literature (99-101). There are also on-going trials evaluating
the role of CA125 as a primary test followed by ultrasound scanning as a secondary
screen. Preliminary data is promising for this sequential strategy, showing some
improvement in the overall sensitivity and specificity (102, 103). The role of several
other tumour markers as screening tools for EOC such as CA19-9, CA15-3, MCA,
PLAP and MOV-1 are currently being investigated (89, 90).
1.5.2 Surgery
The role of primary surgery can be broadly classified into 3 categories. The first aim
is to make a definitive diagnosis of ovarian cancer. Once established, the clinical
staging of this disease is performed by systematic examination of the pelvic organs,
omentum, subdiaphragmatic areas, anterior abdominal wall, paracolic gutters,
surface of the small and large bowel and palpation of pelvic and para-aortic lymph
nodes (7). Accurate staging is of vital importance in planning further treatment for
the patient. The third aim of primary surgery is therapy. Optimal cytoreductive
surgery minimally involves total hysterectomy, bilateral salpingoopherectomy and
omentectomy, with the aim of leaving less than 2 cm of macroscopic disease.
Seventy percent of patients present with cancer that has spread beyond the ovaries
and optimal cytoreduction is generally achieved in three-quarters of this population
(7). As mentioned previously, the volume of post-operative residual disease is a
powerful prognostic indicator of disease outcome, even in patients with extra¬
peritoneal metastases (60, 61, 65, 66). However, the value of more radical surgery
involving pelvic and para-aortic lymphadenectomy in achieving optimal
cytoreduction is controversial (104-111). Certainly Lymph Node (LN) status is
included in FIGO staging (Table 2). Nevertheless, there is considerable evidence to
suggest that widespread peritoneal involvement of the cancer (FIGO III & IV) is
significantly more unfavourable than lymphatic invasion, and removal of diseased
nodes does not appear to influence patient survival (106, 112, 113). However, the
debate regarding LN resection in tumours confined to the ovaries (FIGO I) is not so
clear. Most stage I tumours are removed by general gynaecologists and LN resection
is not routinely performed, partly due to the lack of expertise for this complicated
procedure. Numerous studies have reported 15-25% LN involvement in these
apparently early stage tumours (105, 114), and patients with positive nodes have a
significantly worse outcome than those with negative nodes (105, 106). Those with
apparent stage I disease but positive nodes, would automatically be upstaged to IIIC
under current FIGO classification and adjuvant therapies (not necessarily given in
stage I disease) would need to be initiated. However, the 5-year survival in these
patients with no disseminated peritoneal disease exceeds 60%, which is considerably
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more than those with IIIC disease involving peritoneal metastases. Indeed there has
been a proposal that perhaps the FIGO staging should be modified to separate
patients with solely retro-peritoneal metastases from those with intra-peritoneal
dissemination.
In addition to the radical procedure of lymphadenectomy, the issues concerning
bowel and bladder resection with the aim of achieving optimal tumour debulking,
have been reported but to a lesser extent. There is some support, for en-bloc removal
of the recto-sigmoid segment with the tumour mass if densely adherent, but
otherwise bowel resection should only be performed if eminent obstruction is
suspected (115, 116).
Lastly, a conservative approach may be employed in a young woman wishing to
preserve her fertility with well differentiated stage I disease. However, it is
recommended that the remaining ovary be removed after child bearing is complete,
as the future risk of developing ovarian cancer is unknown.
Although subsequent surgery is often employed to treat metastases, these procedures
are predominately palliative.
1.5.3 Chemotherapy and Radiotherapy
Whole abdominal radiation therapy is rarely used in the treatment of ovarian cancer.
The dose required to achieve an effective response is curtailed by the ensuing
damage to kidneys and liver. Side effects of radiation to bowel and bladder are
severe and generally unacceptable. However, radiation is occasionally useful for
palliation to relieve pressure symptoms in the pelvis, vaginal bleeding and metastatic
deposits in the brain and bone (7).
Chemotherapy has supplanted radiation therapy as the modality of treatment
following primary surgery. Before 1980, the only drugs with significant efficacy in
treating ovarian cancer were the alkylating agents and doxorubicin (117). Platinum
based compounds, such as cisplatinum and carboplatinum, were introduced into
treatment scheduling in the mid-eighties (118), followed 10 years later by taxane
based compounds. Over the past 5 years, clinical trials by the Gynaecologic
Oncology Group based in the United States, and international collaborative trials by
the European and Canadian consortiums have compared the use of
cisplatinum/placitaxel regimes versus the traditional combination of
cisplatinum/cyclophosphamide as primary adjuvant therapies in ovarian cancer (119-
121). In patients receiving placitaxel in combination with a platinum-based
compound, seventy-five percent attain some disease regression. However, the
cumulative toxicity, especially neurotoxicity, curtails the use of these agents beyond
6 cycles (122). In those patients with minimal residual disease, 50% achieve a
complete response as determined by second look surgery although, even in this
population, a significant number of patients proceed to develop recurrent disease,
with the overall time to recurrence being 16-18 months. Median survival is reported
as approximately 38 months (120). In comparison only 60% of patients showed
some response to cisplatinum /cyclophosphamide, with only 31% achieving a
complete response. Median time to recurrence is 13 months and overall survival 24
months. Currently, the standardised regime in practice following surgical resection
of EOC, is the use of placitaxel in conjunction with a platinum-based compound for
6 cycles.
However, 25-30% of EOC is resistant to drug manipulation and progression is rapid
after primary surgery. In those patients with a partial or complete response after
initial treatment, many develop recurrent disease that is generally resistant to further
use of platinum based compounds. Placitaxel and topotecan are of some use in this
latter population and are presently being evaluated in phase III trials (123-125).
1.5.4 Gene therapy
Gene therapy is defined as the treatment of disease at the level of the underlying
genetic defect. It involves transferring nucleic acids into target cells for the purpose
of perturbing or correcting some pathophysiological process. It was originally
conceived and used in the treatment of inherited monogenetic defects such as
adenosine deaminase deficiency and cystic fibrosis (126). Such a genetic strategy
seems rational given the recognition that tumours typically develop in a progressive
manner as demonstrated in familial adenomatous polyposis and colorectal cancer
(127, 128). However, a progression model for the development of ovarian cancer
has not been identified. Therefore it is unknown which genes are mutated in the
early development of this cancer. Given the numerous alterations that may eventually
result in tumour development and progression, there is no obvious single choice for a
therapeutic gene. Although expertise in this field is rapidly expanding the search for
an ideal target vector for gene delivery presents another challenging obstacle (126,
129). Despite this, a phase 1 international clinical trial is underway to evaluate
whether an adenoviral vector containing wild type p53 given intraperitoneal in
conjunction with traditional adjuvant chemotherapy, will improve survival of
patients with ovarian cancer and increase chemotherapy efficacy. This appears to be
premature given the controversial results of mutated p53 overexpression correlating
with patient survival and progression-free interval and the present system for gene
delivery. Other genes being subjected to clinical trials in breast and ovarian cancer
include Her-2/neu and BRCA1 (130, 131).
1.6 Conclusion
Ovarian cancer is a common disease in western societies with a poor clinical
outcome. Advances in the surgical and chemotherapeutic management has
significantly improved the quality of life of patients suffering with this disease, but
have yet to make a dramatic difference in determining the clinical outcome of these
patients. Although several clinical and pathological markers of disease outcome in
ovarian cancer have been identified, there is a need for molecular markers that could
reliably predict the overall survival and progression-free interval of patients. In
addition, a better understanding of tumour biology may lead to new and more
effective therapies in treating ovarian cancer.
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Chapter Two Molecular genetics of ovarian cancer
2.1 Introduction
Cancer development and progression is thought to result from an accumulation of
mutations in multiple genes that are important for normal cellular function, that
ultimately leads to uncontrolled proliferation and tumour growth (127). Subsequent
mutations may select for more aggressive events such as invasion into surrounding
tissue and metastases. Aberrant expression of oncogenes stimulates this process and
tumour suppressor genes inhibit it. Abnormal activation of oncogenes and
inactivation of tumour suppressor genes have been identified as essential steps
during carcinogenesis. Over 100 putative proto-oncogenes and tumour suppressor
genes have been described although only a few have been studied in ovarian cancer
(132). The list is likely to grow rapidly with the utilisation of DNA microarray
technology to identity novel genes involved in ovarian tumourigenesis. A summary
of genetic mutations identified in ovarian cancer is presented in Table 2.1.
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Table 2.1 Common genetic mutations identified in ovarian cancer
X
(Chromosome)
Ref. Mutation Genes implicated to
be involved in ovarian
cancer
3 (148, 149) Deletion 3p21.1-22





5 (150, 151) 5q LOH
5q33.3-5q34




7 Deletion 7q31.1-31.3 Putative TSG - yet to be
identified
8 (152) 8q24 c-MYC 30% over
expression/amplification
9 (153) LOH 9p21, 9q31, 9q32-34 p16lnk4a Mutations rare
plFnk4b
d1^rf







12 (157) 12p13 P27Klp1 40% EOC loss of
expression (CDKI)
K-RAS 5-30% altered in
EOC.
13 (147, 158) Mutation at 13q12-13
LOH 13q14
BRCA2
Rh LOH 30-40% in EOC.
However LOH does not




Allele loss at 17p13.1-13.3
LOH 17q21







18 (165) 18q LOH Advanced stage, locus near
DCC gene
X (166) Loss of X Possible early event in
tumour development
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The genes relating to cell cycle regulation are discussed in detail in subsequent
sections. However, some of the other genes that have been studied extensively in
ovarian cancer warrant further mention.
HER-2Ineu (erbB-2) is located on chromosome 17q21-22 and encodes a 185 Kda
transmembrane glycoprotein with tyrosine kinase activity. The phosphorylation
cascade mediated by this oncoprotein promotes cell proliferation and differentiation
through activation of the RAS-GTP signalling pathway (133). Gene amplification
and/or protein overexpression has been observed in several types of tumours (134-
136). In ovarian cancer, HER-2/neu overexpression occurs in approximately 30% of
cases and correlates with poor survival. One possible explanation for this finding, is
that HER-2/neu overexpression may result in cellular resistance to platinum-based
chemotherapy regimes (137, 138). A recent clinical trial in metastatic breast cancer
patients, found a significant improvement in disease response rates to cisplatinum
when combined with an anti-HER-2/neu antibody (Herceptin) (139). Anti-HER-
2/neu antibody also appears to mediate an increased sensitivity to cisplatinum in
chemoresistant ovarian cancer cell lines containing multiple copies of HER-2/«ew
(140). However, a recent phase I trial utilising an anti-erbB-2 single-chain antibody-
encoding adenovirus in patients with advanced ovarian cancer, failed to show any
clinical benefit despite no obvious dose-limiting, vector-related toxicity (141).
The BRCA1 gene is located on chromosome 17q21 and encodes a large 220 kDA
protein expressed most abundantly in testis, breast and ovarian tissue (142). BRCA1
is thought to function as a tumour suppressor gene, as the normal copy of BRCA1 is
invariably deleted in ovarian cancers that arise in women who inherit a mutant
BRCA1 gene. In addition, the introduction of wild-type BRCA1 has been shown to
inhibit growth of some breast and ovarian cancer cell lines (143). However, the
exact cellular functions and interactions of the protein product remain unknown.
Chromosomal mutations have been reported in approximately 50% of hereditary
ovarian cancer families and carriers of these germ-line mutations have a 30-80% life¬
time risk of developing ovarian or breast cancer (144). Loss of heterozygosity at the
BRCA1 locus occurs frequently in sporadic ovarian cancer, although somatic
mutations of the remaining copy are rarely observed. Preclinical studies have
demonstrated that intraperitoneal injection of retroviral vectors expressing
BRCAlsv, a normal splice variant of BRCA1, can inhibit the growth of established
intraperitoneal tumours in a nude mouse xenograft model (145). An initial phase 1
clinical study using intraperitoneal infusions of BRCAlsv in patients with advanced
ovarian cancer, reported promising results relating to vector stability, minimal
toxicity and the absence of an anti-BRCAl antibody response (130). However, a
subsequent phase II trial by the same group was prematurely terminated due to
conflicting results of vector stability, the rapid development of anti-BRCAl
antibodies and importantly, no disease stabilisation (146). A second breast/ovarian
cancer susceptibility gene (BRCA2) has been identified that maps to chromosome
13ql2 (147). Ovarian cancer has been reported to occur in 10-35% of carriers with
hereditary BRCA2 mutations (133). Similar to BRCA1, loss of heterozygosity at the
BRCA2 locus is frequently observed in sporadic ovarian cancer, but somatic
mutations remain rare (147).
Methylation-induced silencing of the BRCA1 promoter with consequent reduction in
BRCA1 mRNA has been demonstrated in 15% of sporadic breast and ovarian
cancers. This does not appear to be the case in other solid tumours and indirectly
may provide evidence for its pathological significance. In contrast, the BRCA2
promoter has been shown to have few or no methylated dinucleotides in sporadic
ovarian tumour DNA when compared with non-tumour DNA. Indeed in these cases
BRCA2 mRNA is significantly elevated. It is also possible that downstream BRCA-
interacting proteins may be affected by other events producing carcinogenic sequalae
similar to those resulting from BRCA dysfunction. As previously mentioned the role
of role of BRCA is largely unknown and with an increasing understanding may be
shown to play a significant role in the development of sporadic tumours.
2.2 Cell cycle regulation
Regulation of cellular proliferation by external mitogens is governed through
receptor mediated signalling pathways, which ultimately converge on cell cycle
genes. The aberrant expression of cell cycle genes, resulting in cellular disruption,
has been implicated in the development ofmost human cancers. In order for cells to
replicate, they must pass through four distinct phases Gi, S (DNA synthesis), G2 and
M (Mitosis). Progress through these phases is regulated by molecular checkpoints to
ensure DNA and cellular integrity prior to cell division (167). The orderly transition
of cells through Gi is the most critical step in this process. It is the restriction point
in mid to late Gi that determines whether a cell progresses to cell division, cell cycle
arrest, cellular differentiation or apoptotic cell death. Progress to this point in Gi
requires a balance between positive and negative regulatory factors. The interaction
of these factors (cyclins, cyclin dependent kinases (CDK's) and cyclin dependent
kinase inhibitors (CDKI's)) is crucial for the eventual phosphorylation of pRb (168-
171). Phosphorylation inactivates pRb, which results in the release of the E2F
family of transcription factors that in turn activate a set of target genes that are
essential for entry into S phase (172, 173). There are two important pathways
responsible for the phosphorylation hence inactivation of pRb, which include cyclin
D l/CDK4-6/p 16Ink4a and cyclin E/CDK2/p27Kipl. Both these pathways are
influenced by the CDKI p21Wafl/Cipl, the levels of which are regulated by p53. A
schematic diagram illustrating the events that lead to the phosphorylation of pRb is
shown in Figure 2.1.
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The retinoblastoma gene was the first well-defined tumour suppressor gene. Familial
retinoblastoma is a disease in which children develop retinal tumours that often
affect both eyes (174). Allelic loss at the Rb locus was found in such individuals,
with mutations demonstrated in the remaining copy (175, 176). Its role as a tumour
suppressor gene was confirmed by experiments on Rb knockout mice. Mice
homozygous for Rb mutations died in-utero because of defects in haematopoiesis and
neuronal cell death, and although heterozygote (Rb +/-) mice were viable, many
spontaneously developed thyroid and pituitary tumours (178). Subsequent
experiments in those mice developing tumours revealed loss of the remaining wild
type Rb allele (177,178).
pRb is a 928 amino acid nuclear phosphoprotein encoded by a gene on chromosome
13ql4 (179). Rb gene mutations have been described in a wide variety of human
neoplasms including gall bladder, breast and lung cancers (180-182). Loss of
heterozygosity at the Rb locus is a reported frequent event in epithelial ovarian
cancers, but is rarely associated with altered pRb expression (183, 184).
The putative role of cyclins as oncogenes has strengthened in the past few years.
They are pivotal in binding to, and directing CDK's (185) to appropriate substrates,
and phosphorylating them during specific phases of the cell cycle. Regulators of Gi
progression in mammalian cells include D-type cyclins (Dl, D2, D3) and cyclin E
(169). D-type cyclins associate with CDK4 and CDK6 initiating pRb
phosphorylation in mid-Gj (173, 186), while cyclin E binds to CDK2 and completes
phosphorylation of pRb later in the Gi phase (187). The most strongly implicated of
the D-type cyclins, in neoplastic transformation of cells is cyclin Dl (188).
Experiments show that when cyclin Dl is overexpressed in fibroblasts, pRb is
phosphorylated earlier and progression through Gi is accelerated (189). Conversely,
when anti-cyclin Dl antibodies are injected in early to mid-Gi phase, cell cycle arrest
is observed. The gene encoding cyclin Dl is located on chromosome llql3
('CCND1). Dysregulation of CCND1 can occur through several mechanisms. In
parathyroid adenomas an inversion involving llql3 and 1 lql5 results in CCND1
coming under the control of the parathyroid gene promoter (190, 191). In B cell
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lymphomas a reciprocal chromosomal translocation occurs at the Bell breakpoint
and expression of CCND1 is regulated by the immunoglobulin heavy chain enhancer
(192, 193). However, amplification of CCND1 is the most common route of cyclin
D1 overexpression in many solid tumours including head and neck, breast and
pancreas (194-197).
Cyclin E accumulates in late Gi, and is downregulated in S phase (198).
Transcription of cyclin E is activated by the initial phosphorylation of pRb. E2F
transcription factor complexes negatively regulates the cyclin E gene promoter, and
phosphorylation of pRb results in the release of this inhibitory mechanism (199).
Regulation of cyclin E protein levels is not fully understood. Gene amplification has
been observed in a small proportion of breast and colorectal tumours with abnormal
protein expression found to correlate with advanced stage and poor grade in breast
carcinomas, suggesting its potential role as a prognostic marker (195, 200).
The activities of cyclin-CDK complexes are regulated by CDKI's. CDKI proteins
are grouped into two categories based on their protein sequence homologies and
putative CDK targets. The first family include the Cip/Kip proteins whose actions
broadly affect the activity of cyclin D-, E- and A-dependent kinases. The second
class includes the Ink4 proteins that specifically inhibit the catalytic subunits of
CDK4 and CDK6(171).
A conserved amino-terminal domain, but highly divergent carboxyl-terminals define
the structural and functional diversity of the Cip/Kip family members that include
p21Wafi/Cipi^ p27Klp! ancj p57K'P2. The gene encoding p2lWafl/Cipl is located on
chromosome 6p21.2 and contains 3 exons of 68, 450 and 1600 base pairs (201). The
amino terminus of p21Wafl/Cipl protein binds cyclin-CDK complexes whereas the
carboxyl end contains PCNA binding and inhibitory activity (202). p21Wafl/Cipl is
involved in inducing growth arrest, terminal differentiation and apoptosis of cells
(203). Although, gene mutations are rarely present in human cancers (204, 205) loss
of protein expression is frequently observed (206-208).
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p21Wafl/Cipl protein levels are predominately regulated at the transcriptional level
(203). Wild type p53 induces p21Wa^1/CipI transcription in response to DNA damage
through direct interaction with p53-binding consensus sequences in the p21WafI/Cipl
promoter region, thus exerting its growth suppressive effects (209). Initially thought
to be a surrogate marker of p53 function, there is now considerable evidence that
p21Wafl/Cipl can exert inhibitory effects on the cell cycle and induce apoptosis
independent of p53 expression. Studies using fibroblasts from p53 knockout mice,
breast cancer cells with known p53 mutations and TGF(3 activation of ovarian cancer
cell lines lacking functional p53 have demonstrated upregulation of p2lWafl/Cipl
independent of p53-induction (210-212).
p27K,pl is another member of the Cip/Kip family. A gene located at chromosome
12pl2-12pl3.1 encodes p27Kipl. Point mutations and homozygous deletions are rare
events in the development of human cancers (157), and levels of p27Kipl protein are
predominately regulated at the posttranscriptional level through degradation by the
ubiquitin pathway (213). p27Kipl levels are high in quiescent cells and decrease
during G1 phase reaching the lowest point in S phase. This differential decrease is
due to a shorter half-life of the protein in Gi as a result of a 6-8 fold increase in
degradation (171).
The inhibitory mechanism of p27Kipl is not fully understood. In Gi arrested cells,
p27Kipl is preferentially bound to cyclin E/CDK2, although during proliferation it
appears to be associated with cyclin Dl/CDK and cyclin A/CDK complexes (214).
It is this sequestration of p27Kipl from cyclin E/CDK2 to cyclin Dl/CDK complexes
that appears to favour progression into S phase. Transgenic p27KipI knockout mice
display features of multi-organ hyperplasia, hypertrophy and tumourigenesis (215-
217). In addition to CDK inhibition, there is also evidence to suggest that
overexpression of p27Kipl induces apoptosis in different cancer cell lines (218) and
levels may also relate to the degree of differentiation of the tumour type (171).
Decreased expression or loss of p27Kipl has been shown to correlate with poor
prognosis in patients with breast, prostate, colorectal and gastric cancers (219-222).
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Ink4, the second category ofCDKI's includes pl5Ink4b, pl6Ink4a, pl8Ink4c and pl9Ink4d.
pidink43 is the most comprehensively studied within this group (223). pld1^4®
specifically targets CDK4 and prevents the association of CDK4 with cyclin D1
thereby inhibiting phosphorylation of important downstream targets (224). Somatic
mutations, homozygous deletions or DNA methylation of the pl6Ink4a gene located
on chromosome 9p21, have been detected in a high percentage of human cancer cell
lines and some primary tumour types (225, 226). Levels of plb1^43 are
predominately regulated by the ubiquitin-proteosome pathway. Other observations
suggest that a bi-directional feedback loop may exist between pRb and pl6Ink4a. Li et
al., (1994), (227) demonstrated that transcription ofpl6Ink4a is suppressed by pRb in
cultured cells, and Fang et al., (1998), (228) showed that pRb is transcriptionally
repressed by pl6Ink4a. Consistent with these findings, pl6lnk4a gene deletion and pRb
deficiency are reported to be inversely correlated in some tumour types (180). In
addition, an association between altered cyclin D1 and pRb in oesophageal tumours
has also been reported (229).
The cell cycle regulatory effects of the nuclear phosphoprotein p53 are also manifest
in the G1 phase. Wild type (wt) p53 nuclear phosphoprotein, consisting of 393 amino
acids, is the product of a tumour suppressor gene located in the short arm of
chromosome 17. This modular protein has several functional domains (230). The
amino-terminal region binds to a target DNA sequence, promoting transcription and
thereby activating the expression of particular genes. These include genes involved
in cell cycle arrest (e.g. p21, GADD45, mdm-2) (231) and those modulating
apoptosis (e.g. BAX, Bcl-2) (232). The carboxyl-terminal region is responsible for
the formation of stable tetramers, the form in which wt p53 is found. Adjacent to
this, there is a region involved in the recognition and repair of damaged DNA.
Under normal conditions wt p53 is expressed at low levels, does not interfere with
routine cellular functions, and has a short half-life of only a few minutes (233).
However, following a stress signal such as hypoxia or DNA damage, there is a rapid
increase in levels of wt p53, and subsequent phosphorylation and acetylation results
in its activation as a transcription factor. Consequently, it can induce cell cycle
arrest, DNA repair, or apoptotic cell death.
Inactivation of this tumour suppressor gene is implicated in the development ofmore
than 50% of all human cancers (162). Common abnormalities include loss of
heterozygosity (LOH), missense mutations, re-arrangements, frame shift mutations
and deletions. The majority of mutations in ovarian cancer are missense mutations
that are present in the highly conserved domains involving exons 5 to 8 (161, 234).
The resultant abnormal p53 protein has the ability to hetero-dimerize with wt p53
rendering it inactive. Moreover, some mutated p53 proteins can enhance
transformation and progression of cells when injected into wt p53 nullizygous cells,
suggesting properties other than hetero-dimerization with wt p53 contribute to
cellular alterations (162, 235). Mutated p53 protein is generally resistant to
degradation and has a prolonged half-life, which allows its detection by
immunohistochemical staining (161, 236, 237). These properties offer a simple
approach for studying the role of p53 gene alterations in clinical material but
assumes concordance between p53 mutations and positive protein staining. Several
studies have demonstrated a significant correlation between p53 mutations and
aberrant protein expression, especially for missense mutations that are present in a
high percentage of ovarian cancers (238). The role of truncating mutations resulting
in no protein expression is discussed in chapter 5. p53 mutation and/or protein
overexpression is predictive of poor clinical outcome of patients with many different
types of cancers (208, 239, 240).
In conclusion, progress through the cell cycle, in particular G1 to S phase transition
is regulated by complex interactions between positive and negative regulators that
ultimately determine whether the cell is committed to division, growth arrest,
differentiation or apoptosis. Section 2.3 examines the published evidence for
deregulation of specific cell cycle genes in epithelial ovarian cancer.
2.3 Aberrant expression of specific cell cycle genes in epithelial
ovarian cancer
2.3.1 p53
Gene mutations and/or overexpression of p53 have been detected in 30-80% of
epithelial ovarian tumours (234, 241-243). However the prognostic role of aberrant
p53 expression in determining the outcome of patients with epithelial ovarian
tumours is far from conclusive. Several studies have identified p53 overexpression as
an adverse prognostic factor in EOC (234, 241-245), although only two have shown
it to be independently prognostic when analysed with clinicopathological
determinants of disease outcome (242, 243). In contrast, there are a number of
studies that suggest expression of p53 has no prognostic value in EOC (246-249).
Interestingly, the data presented by Antilla (242), Eltabbakh (241) and Klemi (243),
demonstrate that p53 overexpression co-segregates significantly with tumours of
serous origin. Epithelial ovarian tumours constitute several subtypes distinguishable
on histology and have subtle biological and behavioural differences. For example
clear cell carcinoma is more aggressive than other types of epithelial ovarian tumours
(8). Hence, a major reason for contradictory findings in the published literature may
be the variant nature of the tumour cohort. Further controversies exist regarding the
role of p53 expression in chemoresistant ovarian tumours. In approximately 20% of
patients, EOC-is refractory to chemotherapeutic intervention. These agents
commonly promote tumour regression by inducing apoptosis, a process in which p53
has a crucial role. Marx (1998) (250) and Buttitta (1997) (251) both found a
significant relationship between p53 overexpression and chemoresistant disease, in
contrast to findings published by Van der Zee (1995) (252) and Renninson (1994)
(253). A summary of published data on p53 alteration and clinical outcome in EOC
is shown in Table 2.2. The studies were identified by a systematic search on
Medline using the key words, ovarian cancer and p53. Studies not related to survival
and/or correlation to clinicopathological features of ovarian cancer are not included
in this table.
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Table 2.2 Literature review of p53 alteration and clinical outcome in
ovarian cancer.



























































































































































































































Mix: Mixed Epithelial Cancer
NS: Not significant
EOC: Epithelial Ovarian Cancer
2.3.2 Cyclin Dependent Kinase Inhibitors: p2iWaf1/clp1, p27Klp1, p16lnk4a
The role of altered p21WafI/Cipl expression as a prognostic biomarker has been
investigated in a range of human cancers. Loss of p2iWafl/ClP1 expression is
significantly associated with reduced survival of patients with bladder, oesophageal
and oral cancer (206-208). However, its prognostic role in ovarian cancer is not
clear. While several studies have examined the expression of p2iWafl/Cipl in EOC
(244, 245, 249, 255-257), only 2 have reported a significant association with clinical
outcome (244, 255). However, both these studies found p2lWafl/Cipl was not an
independent prognostic factor when stratified with clinicopathological determinants
of disease outcome in multivariate analysis. One other study warrants mention.
Costa et al., (1999), demonstrated an independent prognostic role of p2]Wafl/Cipl
expression and disease outcome in epithelial tumours, although the value of this
result is questionable. The cohort contained cancers of peritoneal and ovarian origin,
different histological subtypes and was inclusive of borderline tumours for survival
analyses (258).
Expression of p2iWafl/Cipl is predominately regulated by wt p53 although as
mentioned previously, p53-independent mechanisms of induction are likely to exist.
In some studies of ovarian cancer, failure to demonstrate a correlation between
p2iWafl/Cipl eXpression and p53 alteration supports a p53-independent mechanism of
induction (245,.255). In addition, although Anttila et al., (1999), demonstrated a
significant co-segregation between these 2 molecules in a large series of ovarian
tumours, they reported increased power in predicting clinical outcome when
combining the abnormal expression of p53 and p2iWafl/Cipl than either alone (244).
Several other authors (234, 238, 244) have also supported this finding. A summary
of the published data on p21Wafl/Cipl expression and clinical outcome in ovarian
cancer is shown in Table 2.3.
36
Table 2.3 Literature review of aberrant p2iWa,1/Cip1 expression and
clinical outcome in ovarian cancer.
Overall survival Progression-free
survival



















0.033 NS NS No association with
p53 expression.
























NS NS No association with

































0.012 NS NS Expression associated
with subtype, grade,



















































SEN's: Surface epithelial neoplasms (including primary peritoneal and ovarian tumours)
S: Serous U: Undifferentiated NS: Not significant
M: Mucinous Misc: Miscellaneous EOC: Epithelial Ovarian
E: Endometrioid Mix: Mixed Epithelial Cancer Cancer
CC: Clear Cell TCC: Transitional cell carcinoma
smcc: Small cell carcinoma
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Decreased expression or loss of p27Kipl correlates with poor prognosis in patients with
breast, prostate, colorectal and gastric cancers (219-222). The literature pertaining to
expression in ovarian cancer is limited. Newcombe et al., (1998), were first to report
an independent survival advantage beyond 5 years in patients with ovarian tumours
demonstrating high p27Kipl levels. The multivariate analysis was modelled against
accepted clinical prognostic parameters of stage, grade, performance status and
residual disease (259). However, a subsequent larger study by Baekeland et al,
(1999), incorporating 185 patients failed to confirm this result (257).
Deletions and point mutations in the pl6Ink4a gene are common in a variety of
tumours including oesophageal cancers, squamous cell carcinomas of the head and
neck and glioblastomas (229, 260-262). Loss of heterozygosity ofpl6lnk4a occurs in
30 - 40% of ovarian tumours although mutations of the remaining allele are rare,
which raises the possibility that hypermethylation of the pl6Ink4a gene promoter may
result in decreased transcription of this gene. However, in serous ovarian tumours
there is no evidence to suggest that methylation of the pl6Ink4a gene occurs (153,
263). Posttranscriptional modification or enhanced degradation may also be
responsible for altered expression of plb11*43 (153). Aberrant expression of pl6Ink4a
has not been shown to be prognostic in epithelial ovarian tumours (153, 263).
2.3.3 Cyclins: Cyclin D1, cyclin E
Cyclin D1 overexpression with or without gene amplification has been identified as
an adverse prognostic biomarker in lung (264), pancreas (265), and tongue
carcinoma (261). Gene amplification or rearrangement is rare in ovarian cancer
(155), although increased levels of mRNA and overexpression of protein has been
reported in 14%-95% of invasive tumours (155, 266, 267). External mitogenic
signalling and regulation by other molecules integral to Gl/S phase progression may
account for this over expression.
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The literature pertaining to cyclin D1 expression and clinical outcome in ovarian
cancer is limited, and only one study has demonstrated a prognostic role for this
protein in EOC. Barbierra et al., (1999), reported a significant relationship between
cyclin D1 overexpression and shorter progression-free interval in a small series of 24
patients with invasive ovarian malignancy (267). This subgroup of patients was
derived from a larger study in which the authors were investigating cyclin D1
expression at the mRNA and protein level in benign, borderline and invasive ovarian
tumours. The authors also found higher cyclin D1 levels in serous EOC and
advanced stage disease. In contrast to this latter association with advanced features
ofmalignancy, three studies have reported significant overexpression of cyclin D1 in
borderline and well differentiated tumours (155, 266, 268). The reason for this is
unclear and the authors postulate that deregulation of cyclin D1 may be an early
event in the development of ovarian cancer. A further explanation cited is that many
borderline and some low grade tumours may be distinctly different lesions and have
pathogenesis different from that of higher grade cancers. Other studies have reported
no association between protein expression and features of malignancy (269, 270).
The role of cyclin D1 in the pathogenesis of ovarian cancer is controversial and
larger studies are required to determine its relationship to features of malignancy and
clinical outcome. A summary of the published data on cyclin D1 expression and
clinical outcome in ovarian cancer is shown in Table 2.4.
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Table 2.4 Literature review of cyclin D1 expression and clinical outcome
in ovarian tumours























Significant increase in mRNA
levels from benign to borderline
to invasive tumours.
24 patients with invasive
EOC evaluable for clinical
outcome. Significantly
shorter PFI in those with
cyclin D1 overexpression
on univariate analysis.







(all subtypes of EOC,
numbers not specified)
Immunohistochemistry study.
Significant reduction of cyclin D1
and p27KIP1 expression in benign
to borderline to invasive
tumours. (In EOC, increased
levels of cyclin D1 expression in
grade 1 cancers compared to



















No association with tumour
grade or clinical stage.


















mRNA analysis (Northern blot).
Increased cyclin D1 transcript
levels significantly associated
with grade 1 and 2 tumours.














Increased cyclin D1 levels
associated with borderline or
well differentiated tumours.
Not investigated.






Mix: Mixed Epithelial Cancer
Oth: Others (type not mentioned)
NS: Not significant
EOC: Epithelial Ovarian Cancer
Cyclin E gene amplification and protein overexpression correlates with advanced
stage and poor grade in a small proportion of breast and colorectal cancers,
suggesting its role as an adverse prognosticator in these cancers (195, 200). Very
little is known about cyclin E expression in ovarian cancer. Gene amplification has
been observed in approximately 20% of ovarian tumours and this correlates with
increased cyclin E mRNA levels. Cyclin E mRNA or protein overexpression did not
correlate with clinical outcome or other clinicopathological features of ovarian
malignancy (271, 272). The only positive finding relating to cyclin E expression in
ovarian cancer, is that expression appears to be high in clear cell carcinomas and low
in serous subtypes of EOC.
2.3.4 pRb
Rb gene mutations have been described in a wide variety of human neoplasms
including gall bladder, breast and lung cancers, and loss of pRb is associated with
poor clinical outcome in these tumours (180-182). Allelic loss at the Rb locus occurs
in 30-70% of ovarian cancers, although corresponding loss of pRb is rare (158, 183,
184, 273) possibly suggesting involvement of another gene at this locus. Most
epithelial ovarian tumours, except mucinous cystadenocarcinomas (274, 275), show
high pRb expression using immunohistochemical techniques and expression does not
appear to co-segregate with other tumour characteristics (183). Only one study has
demonstrated low expression of pRb to be associated with poor prognosis in ovarian
cancer (184). In this study reduced pRb expression was an adverse prognostic
marker of survival in FIGO stage 1 patients. Of the stage 1 patients with pRb
expression >50%, all were alive at 5 years, in contrast to 50% survival of stage 1
patients with reduced pRb expression. Todd et al., (2000), suggested that defects
along the pRb/cyclinDl/pl6Ink4a pathway may play a role in the development of
ovarian cancers (276). In a smaller immunohistochemical study the year previously
Kusume et al., (1999), showed abnormal expression in at least one of the four key
genes in the pRb/cyclinDl/Cdk4/ pl6Ink4a pathway was adversely prognostic in
patients with EOC (277).
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2.4 Conclusion and Aims of Thesis
Many oncogenes and tumour suppressor genes have been implicated in the
pathogenesis of ovarian cancer. Several of these genes are important in cell cycle
regulation, in particular during Gi to S phase transition of cellular division. The
aberrant expression of a few of these cell cycle regulatory genes, e.g. p53,
p21Wafi/Cipi anc| Cyclin Dl, have been studied in ovarian cancer, although these
studies have reported conflicting results. In the majority, the number of tumours
investigated is less than 100 and EOC are generally classified as a single entity.
Moreover, the data relating to expression of other cell cycle genes, e.g. cyclin E,
p27Kipl and pi6^, in ovarian malignancy is limited.
The aim of this research was to extend the present literature by investigating the
protein expression of seven cell cycle regulatory genes in a single subtype of
invasive epithelial ovarian cancers, and determine if expression of these genes could
be used as markers of clinical outcome. Serous cystadenocarcinomas is the most
common type of epithelial ovarian tumour, and this histological subtype was chosen
for our study. The genes selected for this study are critical in the two pathways,
namely cyclin Dl/CDK4/p 161111:43 and cyclin E/CDK2/p27Kipl, which converge on
pRb. In addition, we also examined p2iWafl/ClPI that influences the progression of
both pathways and p53 that transcriptionally regulates the expression of p2iWafl/ClP1.
A further aim of this study was to investigate the relationship of biomarkers to each
other and to clinicopathological prognosticators of disease outcome.
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Chapter Three Methods and Materials
3.1 Patient Characteristics
Approval for this study was granted by the South Eastern Sydney Area Health
Service Ethics Committee (Reference number: 00/115). The cohort was selected
from a consecutive series of 272 patients treated for serous epithelial ovarian cancer
at the Royal Hospital for Women, Sydney between 1988 and 1998. After excluding
patients receiving primary treatment elsewhere (n=102), neoadjuvant therapy (n=22)
and lack of representative tissue material (n=14), 141 patients with invasive serous
ovarian cancer were identified for the present study. Census follow up was to March
2001, with a minimum follow up of 36 months.
Retrospective review of all patient files was performed to obtain pertinent data
related to known clinical prognosticators, type of surgery undertaken, adjuvant
therapy received, recurrence and survival. Clinical follow-up for this cohort of
patients was obtained from the medical records and the NSW state register of Births,
Deaths and Marriages. The gynaecology oncology practice at the Royal Hospital for
Women is the largest in Sydney. Three gynaecology oncologists provide this
service. Treatment of patients is standardised and reflects the most current method
of practice. A definitive diagnosis is made on histopathological examination of
resected tissue in accordance with WHO standards after primary laparotomy for
suspected ovarian cancer. All tumours are staged according to the International
Federation of Gynaecology and Obstetrics standards. Patients are followed post¬
operatively by their surgeons on a regular basis dependent upon disease progression.
The median age at diagnosis of patients entered in this study was 60.3 years (33-86
years). All patients underwent surgical resection as their primary diagnostic and
treatment modality. One hundred and thirty two patients received combined
adjuvant chemotherapy of cyclophosphamide or taxol and a platinum based agent,
either cisplatinum or carboplatinum. Only 2 patients did not receive adjuvant
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chemotherapy. One was found to have a well differentiated, stage la cancer and one
with stage IIIc cancer who refused post-operative treatment. One hundred and twenty
patients (89%) were diagnosed with FIGO stage III or greater disease. This rate is
higher than the reported literature but is likely to represent the experience at a tertiary
referral centre where more advanced and complicated cases are generally seen. The
majority of tumours were moderately (48%) or poorly differentiated (47%). One
hundred and two patients (76%) were debulked to residual tumour of less than 2 cm.
Intra-operative ascites was present in 88 patients (66%). Confirmation of ascites
could not be obtained in 1 case. Similarly the performance status of 12 patients was
not recorded in the notes. Of the remaining patients, 86 had a GOG performance
status of 0 (70%) as recorded in the notes. Seven patients died secondary to post¬
operative complications, and of other causes not related to their disease, and were
excluded from disease-specific survival analysis. The 2-year and 5-year disease-
specific survival rate in the remaining 134 patients was 67% and 31% respectively.
One hundred and twelve patients (84%) suffered a relapse in whom the median time
to recurrence was 16 months (6-132 months). Of these patients, 78% had a complete
response of their disease with primary surgery and chemotherapy as defined by
normalisation of CA125 levels or negative second look surgery. The remainder had
either partial response (n=17) to treatment or no response (n=7) to treatment. The
clinical and pathological characteristics of the patient cohort are listed in Table 3.1.
Table 3.1 Clinical and pathological characteristics of patients with
disease-specific follow-up.
Characteristic Patient number Percentage
Aae of patient
«s65 years 84/134 62.7







Well differentiated 7/134 5.2
Moderately differentiated 64/134 47.8
Poorly differentiated 63/134 47
Residual Disease
<2 cm 102/134 76.1
>2 cm 32/134 23.9
Performance Status
0 ! 86/122 70.5















Immunohistochemistry was performed on formalin-fixed paraffin embedded tissue
samples sectioned at 4 microns and mounted on SuperFrost slides (Menzel-Glaser,
Germany). The tissue samples were deparaffinised by soaking in xylene (two times
for 5 minutes each) and rehydrated through graded ethanol. The Vectastain Elite
Avidin-Biotin Complex kit (ABC kit, Vector Laboratories, California) was used as
the detection system and colour development was obtained using 3,3-
diaminobenzidine (DAB kit, Vector Laboratories, California). Counter-staining was
undertaken with Whitlock's haemotoxylin, Scott's "blueing solution" with or without
"light green" before dehydration through graded ethanol and xylene before cover
slipping. Specific protocols for antigen retrieval, antibody dilution, and antigen
staining are summarised below. Serial dilutions and manufacturer's instructions
determined the antibody dilution resulting in the most appropriate staining pattern for
ovarian tissue. The cells representing positive and negative controls were chosen
from published literature with known expression of cell cycle regulatory molecules
secondary to either amplification, mutations or loss of heterozygosity of the
corresponding gene. Representative photomicrographs of positive and negative
controls for each of the antigens are illustrated in Figure 3.1.
3.2.1 p53
Endogenous peroxidase activity was quenched using 3% hydrogen peroxide (H2O2)
in methanol for 5 minutes. The sections were then boiled in a microwave oven in
0.01M citrate buffer (pH 6.0) for antigen retrieval. Twenty-percent normal horse
serum (NHS) in 2% bovine serum albumin in tris-buffered saline (BSA/TBS) was
subsequently used to block non-specific staining for 20 minutes. Slides were then
incubated overnight at 4°C with an anti-p53 antibody. The sections were then
sequentially incubated with biotinylated horse anti-mouse antibody (1:200 dilution
BSA/TBS, Vector laboratories) for 30 minutes. Details of the primary antibody, and
p53 positive and negative cell line controls are listed in Table 3.2.
Table 3.2 Anti-p53 antibody, dilution and positive and negative tissue
controls.
p53 Comment Reference
Clone DO-7 Mouse monoclonal antibody




Positive DU145 Prostate cancer cell line (278)
Negative PC3 Prostate cancer cell line
3.2.2 pRb
The tissue sections were boiled in a pressure cooker containing 1600 mis of 0.01M
citrate buffer (pH 6.0) for antigen retrieval. Endogenous peroxidase activity was
quenched using 1.5% H2O2 in methanol for 10 minutes. Twenty-percent NHS in 2%
TBS for 20 minutes was used to block non-specific staining. Slides were then
incubated overnight at 4°C with an anti-pRb antibody. The sections were then
sequentially incubated with biotinylated horse anti-mouse antibody (1:200 dilution
TBS) for 30 minutes. Detection and colour development of the specimens was
performed as described previously. Details of the primary antibody, and pRb
positive and negative cell line controls are listed in Table 3.3.
Table 3.3 Anti-pRb antibody, dilution and positive and negative tissue
controls
pRb Comment Reference
Clone G3-245 Mouse monoclonal antibody




Positive MCF-7 Breast cancer cell line (279)
Negative MDA-MB-468 Breast cancer cell line
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3.2.3 P21 Waf1/C|P1
Endogenous peroxidase activity was quenched using 3% H2O2 in methanol for 10
minutes. The sections were then boiled in a microwave oven in 0.01M citrate buffer
(pH 6.0) for antigen retrieval. Four-percent skimmed milk for 20 minutes followed
by 40% NHS in 2% BSA/TBS for 20 minutes was used to block non-specific
staining. Slides were then incubated overnight at 4°C with an anti-p21Wafl/Cipl
antibody. The sections were then sequentially incubated with biotinylated horse anti-
mouse antibody (1:200 dilution TBS) for 30 minutes. Details of the primary
antibody, and p2iWafl/ClP1 positive and negative cell line controls are listed in Table
3.4.
Table 3.4 Anti-p21Wa,1/Cip1 antibody, dilution and positive and negative
tissue controls
p2j\ Wa,1/Cip1 Comment Reference
Clone 70 Mouse monoclonal antibody




Positive HMEC 184 Normal breast cell line (279)
Negative BT 549 Breast cancer cell line
3.2.4 p27Klp\ p16lnk4a, cyclin E
The tissue sections were immersed in target retrieval solution, a modified citrate
buffer (TRS, DAKO Corporation, Carpinteria) and the container placed in a boiling
water bath for 30 minutes to perform antigen retrieval (TRS pH 6.1: p27KipI and
cyclin E, TRS pH 9.9: pi6Ink4a). Endogenous peroxidase activity was quenched using
3% H2O2 in deionised water for 10 minutes. The sections were then incubated with
primary antibody in concentrations as shown below for 30 minutes. Biotinylated
secondary antibody (DAKO Corporation, Carpinteria) was subsequently applied
followed by enzyme conjugated streptavidin and substrate chromogen (DAKO
Corporation, Carpinteria) in accordance with the manufacturer's instructions.
Details of the primary antibody and positive and negative tissue controls for each of
the antigens are shown in Tables 3.5 - 3.7.
Table 3.5 Anti-p27Kip1 antibody, dilution and positive and negative tissue
controls
p27Kip1 Comment Reference
Clone 57 Mouse monoclonal antibody




Positive BT 474 Breast cancer cell line (279)
Negative HMEC 184 Normal breast cell line
Table 3.6 Anti-p16lnk4a antibody, dilution and positive and negative tissue
controls
p16lnk4a Comment Reference
Clone 16 P04 Mouse monoclonal antibody
Company NeoMarkers Fremont, CA
Dilution 1:200
Controls
Positive MDA-MB-157 Breast cancer cell line (279, 280)
Negative MDA-MB-231 Breast cancer cell line (280)
Table 3.7 Anti-cyclin E antibody, dilution and positive and negative tissue
controls
Cyclin E Comment Reference
Clone HE 12 Mouse monoclonal antibody




Positive MDA-MB157 Breast cancer cell line (281)
Negative Salivary Gland Normal tissue
3.2.5 Cyclin D1
The tissue sections were boiled in a pressure cooker containing 1600 mis of EDTA
(pH 8.0) to enhance antigen retrieval. Endogenous peroxidase activity was quenched
using 3% H2O2 in deionised water for 10 minutes. A biotin blocking system
(DAKO Corporation, Denmark) was used to block non-specific staining. The
sections were then incubated with primary antibody in concentrations as shown
below for 30 minutes. Biotinylated secondary antibody (DAKO Corporation,
Carpinteria) was subsequently applied followed by enzyme conjugated streptavidin
and substrate chromogen (DAKO Corporation, Carpinteria) in accordance with the
manufacturer's instructions. Details of the primary antibody, and cyclin D1 positive
and negative cell line controls are listed in Table 3.8.
Table 3.8 Anti-cyclin D1 antibody, dilution and positive and negative
tissue controls
Cyclin D1 Comment Reference
Clone DCS-6 Mouse monoclonal antibody




Positive MCF-7M Breast cancer cell line (195)
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Figure 3.1 (A) p53 - cell line control, PC 3, (B) p53 + cell line control, DU 145,
(C) p2iWafl/Cipl _ cell line control, BT 549, (D) p21Wafl/Cipl + cell line control, HMEC
184, (E) p27Kipl - cell line control, HMEC 184, (F) p27Kipl + cell line control, BT 474,
(G)cyclin Dl- cell line control, HBL 184, (H) cyclin D1 + cell line control, MCF-7,
(I) pl6Ink4a - cell line control, MDA-MB-231, (J) pl6Ink4a + cell line control, MDA-
MB-157, (K) cyclin E - tissue control, salivary gland, (L) cyclin E + cell line control,








Two separate observers, including a qualified pathologist, assessed the degree and
pattern of tissue staining of molecular markers for each case. Standardisation of
scoring was achieved by comparison of scores between observers and any
discrepancies were resolved by consensus. Scores were given as an overall
percentage of positive nuclear staining within 10 representative areas of the tumour
sample at x400 magnification. The pattern of immunostaining for all the antigens
was homogenous in this tissue cohort. The percentage values above which
immunostaining was considered as positive for each of the antigens was based on
reports from the published literature. There is a wide range of cut-off values above
which immunostaining is considered as positive staining in the literature, and we
have tried where possible, to standardise our scoring based on the majority consensus
view of what is considered as positive expression. Table 3.9 summarises the
percentage of nuclear staining above which positive staining was considered for each
of the antigens studied.
Table 3.9 Cut-off values for positive antigen staining with associated
references












(263) (266) (266) (277)
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3.3.2 Statistics
An electronic relational database was constructed using Filemaker Pro 4.0 (Claris
Corporation, North Ryde, Australia). This database was designed during the course
of this study, intermittently modified and will be used as an essential resource for
future investigations on this cohort. The information entered was appropriately
coded, de-identified and password protected as per ethics guidelines (approved by
the South Eastern Sydney Area Health Service Ethics Committee). The important
clinicopathological features that were recorded in the database included; date of
diagnosis, age at diagnosis, date of last follow-up or date of death as appropriate,
date of disease progression, pre-operative and follow-up CA125 levels, pre-operative
performance status, details of the primary laparotomy, presence of intra-operative
ascites, volume of residual disease, FIGO stage, type and extent of post-operative
chemotherapy, details of follow-up investigations that including radiology and
second-look surgery, and pathological characteristics of the tumour including type
and differentiation. The percentage of cancer cell nuclei stained for the antigens
examined were also recorded in this database. For statistical analysis, the
information was exported onto appropriate spreadsheets for integration with Statview
4.5 software (Abacus concepts, Berkley, California).
Clinicopathological features reported in the published literature (section 1.4) as being
important determinants of clinical outcome in ovarian cancer include; volume of
post-operative residual disease, presence of ascites performance status, FIGO stage,
tumour grade, and to a lesser extent, age of the patient at the time of diagnosis and
pre-operative serum CA125 level, and CA125 levels prior to the 4th cycle of
chemotherapy. Disease-specific survival was calculated from the date of primary
laparotomy to date of death or date of last follow up. The progression-free interval
was calculated from the date of primary laparotomy to the date of recurrence as
specified by biochemical, radiological or surgical relapse. Patients were categorised
as having a complete response to primary surgery and adjuvant chemotherapy, as
defined by normalisation of CA125 levels or negative second look surgery.
Univariate survival analysis according to these parameters and expression of
molecular markers in this cohort of serous epithelial ovarian tumours, was
determined using the Kaplan-Meier method and Cox proportional hazards model.
Predictive variables of disease outcome on univariate analysis were incorporated into
multivariate analysis using Cox proportional hazards modelling, to identify factors
with independent significance in determining the clinical outcome of patients.
In this study the relationships between the molecular markers themselves and the
correlation between the molecular markers and various clinical and pathological
parameters was also determined. These analyses were performed using chi-square,
Fisher's exact test and simple regression where appropriate. A p-value of <0.05 was




The expression of p53, p21Wafl/Cipl, p27Kipl, cyclin Dl, cyclin E, plb1^43 and pRb
were evaluated by immunohistochemistry on 134 primary serous ovarian cancers.
Clinicopathological determinants of poor clinical outcome (reduced disease-specific
and progression-free survival) included RD greater 2 cm, presence of ascites, poor
performance status (1, 2), advanced FIGO stage (III, IV) and increasing tumour
grade (moderately and poorly differentiated).
Overexpression of p53 occurred in 59% of tumours and was significantly associated
with increasing tumour grade (p=0.03), loss of p2lWafl/Cipl expression (p=0.006),
reduced DSS (p=0.02) and shorter PFI (p=0.004). Similarly, loss of p21Wafl/CipI was
demonstrated in 77% of cancer specimens and was also associated with increasing
tumour grade (p=0.002) and shorter disease-specific (p=0.02) and progression-free
survival (p=0.01). Although an association was observed between the expression of
p53 and p21Wafl/Cipl, when various combinations of p53 and p2lWafl/Cipl expression
were analysed, patients whose tumours displayed overexpression of p53 with
concurrent loss of p2iWafl/Cipl had a significantly shorter DSS (p=0.0008) and PFI
(p=0.0001) than patients with other combinations of these two molecules.
Overexpression of cyclin Dl occurred in 19% of tumours and was associated with
reduced DSS (p=0.03). Reduced expression of p27Kipl was observed in 67% of
tumours and was associated with increasing tumour grade (p=0.04), expression of
p2]Wafi/CiPi (p=o.006) and cyclin Dl (p=0.03) and shorter DSS (p=0.05) and PFI
(0.05). On multivariate analysis using the Cox Proportional Hazards Model,
overexpression of cyclin Dl and a combination of p53 overexpression with
concurrent loss of p2iWafl/Cipl were both independently predictive of reduced DSS,
when adjusted for volume of RD, PS and presence of ascites. p53 overexpression
with loss of p2iWafl/Cipl also retained independent significance as a prognostic factor
for shorter PFI when considered with the same clinical characteristics already
mentioned.
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On further analysis of p53, a differential staining pattern was observed across the
tumour cohort. Less that 5% of p53 nuclear staining was observed in 40% (n=53) of
tumours, greater than 50% staining in 41% (n=55) of specimens with the remainder
(19% (n=26)) demonstrating intermediate expression, i.e. between 5% and 50%. On
Kaplan-Meier survival analysis, only 8% of patients (n=2) that had intermediate
expression of p53 in their tumour specimens were alive at 5 years, in contrast to 5-
year survival rates of 36% and 43% in those with high expression (>50%) and low
expression (<5%) of p53 respectively. This difference was highly significant (p <
0.0001).
4.2 Characteristics of the study cohort and clinicopathological
determinants of disease outcome
The clinical and pathological characteristics of the study cohort have been previously
described in section 3.1. Consistent with published data, the presence of ascites,
large volume of residual disease (>2 cm), advanced stage (III, IV), increasing tumour
grade (2,3) and worse performance status (1,2) were all significant determinants of
reduced disease-specific survival (DSS) and 5-year progression-free interval (PFI).
However, in the analyses of stage and grade of tumour the confidence intervals were
large due to a small number of cases with well differentiated tumours (n=7), and
patients with early stage disease (I & II, n=14), and consequently these results need
to be interpreted with caution. Moreover, there was no survival advantage for
patients with moderately differentiated tumours (n=64) as compared to those with
poorly differentiated ones (n=63). Similarly, there was no difference in DSS and PFI
of patients when analysis was stratified for stage III vs stage IV tumours. Again this
may be due to the small number of patients with stage IV disease (n=18). In
addition, patients could not be stratified by substage of disease predominantly due to
the size of the cohort. The results of univariate analysis using the Cox Proportional
Hazards Model, of clinicopathological characteristics of patients to disease-specific
and progression-free survival are summarised in Table 4.1.
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Table 4.1 Univariate analysis of relationships between clinicopathological
characteristics and disease-specific survival and progression-free interval.
(DSS)* (5-year PFI)*
Clinical Relative 95% CI p-value Relative 95% CI p-value
Parameter risk risk
Residual disease
s2cm vs > 2cm 3.05 1.92-4.86 <0.0001 2.98 1.82-4.40 <0.0001
Stage
l-ll vs Ili-iV 4.35 1.59 -11.90 0.004 3.33 1.61 -7.52 0.001
Grade
1 vs 2-3 5.54 1.32-23.26 0.02 2.34 1.06 -10.58 0.05
Ascites
Yes vs No 2.28 1.39-3.74 0.0006 2.04 1.34-3.19 0.0009
Performance
status: 0 vs 1-2 2.15 1.35-3.44 0.001 1.58 1.03-2.43 0.03
Age
^65 vs > 65 1.31 0.67-1.61 0.87 0.94 0.65-1.43 0.84
CA125
s500 vs > 500 0.77 0.45-1.34 0.36 0.88 0.54-1.43 0.60
❖ Disease-specific survival was calculated from date of primary laparotomy to the
date of disease-specific death or date of last follow up.
* 5-year progression-free interval was calculated from the date of primary
laparotomy to date of disease progression. Data census was at 5 years from date
of diagnosis.
4.3 Cell cycle gene expression in ovarian cancer and correlation
between patterns of expression and clinicopathological
characteristics of the study cohort
The expression of p53, p21Wafl/Cipl, p27Kipl, cyclin Dl, cyclin E, plb11^43 and pRb
were evaluated by immunohistochemistry on 134 primary serous ovarian cancers.
Expression was quantified on the basis of the percentage of positively stained nuclei
and allocated a score to represent the degree of overexpression. The median
percentage of immunostaining, percentage values above which expression was
deemed positive and number of specimens displaying positive staining is shown in
Table 4.2.
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Table 4.2 Immunohistochemical staining of cell cycle genes studied in
serous epithelial ovarian cancer
p53 p21 Wofl/Cipl p27Kpl p16lnWa eye E eye D1 pRb
Range of staining 0-100 0-60 0-95 0-100 0-95 0-60 0-100
(% of positive nuclei)
Median staining 27 4 40 15 20 2 70
(% of positive nuclei)
Cut-off Value >10 >10 >65 >15 >10 >10 >20
(positive staining)
Positive tumours 79 (59) 31 (23) 45 (33) 74 (55) 92 (68) 25 (19) (79)
(percentage)
4.3.1 Clinicopathological and molecular correlates of p53 protein
expression
Increased expression of p53 protein in tumour specimens was considered if >10% of
cancer cell nuclei stained positive for p53 protein. The pattern of nuclear staining
was generally intense and homogenous in the invasive tumour. Representative
photomicrographs of tumour tissue showing positive and negative staining for p53
are presented in Figure 4.1. Expression of p53 correlated to grade (p=0.03), with
14% of well-differentiated tumours staining positive for p53, increasing to
approximately 50% in the moderately and poorly differentiated group. There was no
correlation with between p53 expression and stage (p=0.70), volume of residual
disease (p=0.81) or presence of ascites (p=0.17).
There was no correlation between the expression of p27Kipl, cyclin Dl, and pRb and
nuclear accumulation of p53. However, there was a significant association between
expression of p53 and p2iWafl/ClP1. Of the tumours that overexpressed p53, 14% had
a concurrent increase in p21Wafl/Cipl protein levels, in contrast to p53 negative
tumours where 40% were p2lWafl/Cipl positive (p=0.006). Similarly there was a
significant negative association between p53 expression and pl6Ink4a expression. Of
the p53 positive tumours, 37% demonstrated positive pl6Ink4a expression, whereas in
p53 negative tumours there was positive pi 6Ink4a expression in 62% of tumours
(p=0.004). There was also a weak positive correlation between overexpression of
p53 and positive cyclin E expression. Sixty seven percent of p53 positive tumours
were also positive for cyclin E expression, in contrast to p53 negative tumours where
50% of tumours were cyclin E positive (p=0.04). These associations are
demonstrated in Table 4.3.
Table 4.3 Correlation between p53 expression and clinicopathological
and molecular parameters
p53 (n=134)
Number Positive Negative p-value
>10% <10%
Stage 1 10 (8%) 4 (40%) 6
(n=134) II 4 (3%) 2 (50%) 2 0.70
III 102 (76%) 60 (59%) 42
IV 18 (13%) 10 (55%) 8
Grade 1 7 (5%) 1 (14%) 6
(n=134) 2 64 (48%) 41 (64%) 23 0.03
3 63 (47%) 34 (54%) 29
Ascites No 45 (34%) 21 (49%) 22 0.17
(n=133) Yes 88 (66%) 53 (61%) 34
RD s 2 cm 103 (77%) 59 (57%) 44 0.81





Positive > 10% 11 20 0.006
Negative s 10% 65 38
p27Klp1 (n=134)
Positive > 65% 24 22 0.44
Negative s 65% 52 36
p16lnk4a (n=134)
Positive > 15% 28 36 0.004
Negative <; 15% 48 22
Cyclin D1 (n=134)
Positive > 10% 13 12 0.60
Negative s 10% 63 46
Cyclin E (n=134)
Positive > 10% 51 29 0.04
Negative s 10% 25 29
pRb (n=134)
Positive > 20% 56 44 0.77
Negative <; 20% 20 14
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Figure 4.1 (A) Marked overexpression of p53 in a poorly differentiated
serous ovarian cancer. Insert at x400 magnification. (B) p53 negative
tumour nuclei in a poorly differentiated serous ovarian cancer. (x200
magnification)
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4.3.2 Clinicopathological and molecular correlates of p2iWaf1/clp1 protein
expression
Overexpression of p2iWafl/ClP' in tumour specimens was considered if >10% of
cancer cell nuclei stained positive for p2iWafl/ClP1 protein. The pattern of nuclear
staining was uniform and intense in the invasive tumour. Positive and negative
immunohistochemical staining of p2iWafl/ClP1 in tumour tissue is demonstrated in
Figure 4.2. Expression of p2iWafl/ClP1 correlated strongly to grade (p=0.002), with
71% of well differentiated tumours staining positive for p21Wafl, decreasing
dramatically to 27% and 14% in the moderately and poorly differentiated groups
respectively. There was no correlation between the expression of p2iWafl/CipI and
volume of residual disease (p=0.69), presence of ascites (p=0.28) or stage, although
there was a trend towards decreased expression with increasing stage but this did not
reach statistical significance (p=0.07)
There was no correlation between the expression of plb1^43, cyclin Dl, cyclin E, and
pRb and nuclear accumulation of p2iWafl/ClP1. However, there was a significant
correlate between expression of p53 and p2iWafl/Cipl as mentioned in section 4.1.
Similarly there was a significant positive association between p2iWafl/ClP1 expression
and p27iCipI expression. Of the p2lWafl/Cipl positive tumours, 55% demonstrated
positive p27Kipl expression, whereas in p2iWafl/c'P1 negative tumours there was
positive p27Kipl expression in only 28% of tumours (p=0.006). These associations
are shown in Table 4.4.
Table 4.4 Correlation between p21 Wa,1/Cip1expression and
clinicopathological and molecular parameters
p21 Wafl/Cip1 (n_-|34)
Number Positive Negative p-value
>10% < 10%
Stage I 10 (8%) 3 (30%) 7
(n=134) II 4 (3%) 3 (75%) 1 0.07
III 102 (76%) 22 (21%) 80
IV 18 (13%) 3 (17%) 15
Grade 1 7 (5%) 5 (71%) 2
(n=134) 2 64 (48%) 17(27%) 47 0.002
3 63 (47%) 9 (14%) 54
Ascites No 45 (34%) 13 (29%) 32 0.28
(n=133) Yes 88 (66%) 18(20%) 70
RD s 2 cm 103 (77%) 23 (22%) 80 0.69





Positive > 10% 11 65 0.006
Negative s 10% 20 38
p27Kip1 (n=134)
Positive > 65% 17 29 0.006
Negative s 65% 14 74
p16lnk4a (n=134)
Positive > 15% 16 48 0.71
Negative <; 15% 15 55
Cyclin D1 (n=134)
Positive > 10% 4 21 0.43
Negative <; 10% 27 82
Cyclin E (n=134)
Positive > 10% 16 64 0.29
Negative s 10% 15 39
pRb (n=134)
Positive > 20% 21 79 0.31
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Figure 4.2 (A) Moderate expression of p2lWafl/Cipl in a well differentiated
serous tumour. Insert represents area at x400 magnification. (B) Poorly
differentiated tumour negative for p21 Wafl/ClP' expression. (x200
magnification)
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4.3.3 Clinicopathological and molecular correlates of p27Klp1 protein
expression
High expression of p27Kipl in tumour specimens was considered if >65% of cancer
cell nuclei stained positive for p27Kipl protein. The pattern of nuclear staining was
uniform and intense in the invasive tumour. Positive and negative
immunohistochemical staining of p27Kipl in tumour tissue is demonstrated in Figure
4.3. Expression of p27Cipl/tcipl correlated weakly to grade (p=0.04), with 57% ofwell
differentiated tumours staining positive for p27Kipl, decreasing to 42% and 23% in
the moderately and poorly differentiated groups respectively. There was no
correlation between the expression of p27Kipl and volume of residual disease
(p=0.48), presence of ascites (p=0.39) or tumour stage (p=0.32)
No correlation was observed between the expression of p53, pl6Ink4a, cyclin E, and
pRb and nuclear accumulation of p27Kipl. There was a significant correlation
between expression levels of p27Kipl and p2iWafl/Cipl as mentioned in section 4.2.
There was a weakly significant negative association between p27Kipl and cyclin D1
expression. Of the p27Kjpl positive tumours, 9% demonstrated positive cyclin D1
expression, whereas in p27Kipl negative tumours there was positive cyclin D1
expression in 24% of tumours (p=0.03). These associations are demonstrated in
Table 4.5.
Table 4.5 Correlation between p27Kip1 expression and ciinicopathological
and molecular parameters
p27Klp1 (n=134)
Number Positive Negative p-value
> 65% ==65%
Stage I 10 (8%) 4 (40%) 6
(n=134) II 4 (3%) 3 (75%) 1 0.325
III 102(76%) 34(33%) 34
IV 18 (13%) 5 (28%) 5
Grade 1 7 (5%) 4 (57%) 3
(n=134) 2 64 (48%) 27 (42%) 37 0.04
3 63 (47%) 15(23%) 48
Ascites No 45 (34%) 12(29%) 32 0.39
(n=133) Yes 88 (66%) 32 (36%) 56
RD s 2 cm 103(77%) 37(36%) 66 0.48





Positive > 10% 24 52 0.44
Negative s 10% 22 36
p21wan/cipi (n=134)
Positive > 10% 17 14 0.006
Negative s 10% 29 74
p16lnMa (n=134)
Positive > 15% 23 41 0.71
Negative s 15% 23 47
Cyclin D1 (n=134)
Positive > 10% 4 21 0.03
Negative s 10% 42 67
Cyclin E (n=134)
Positive > 10% 30 50 0.34
Negative s 10% 16 38
pRb (n=134)
Positive > 20% 32 68 0.33
Negative s 20% 14 20
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Figure 4.3 (A) High p27Kipl expression in a poorly differentiated serous
ovarian cancer. Insert represents area at x400 magnification. (B) Absent
p27Kipl expression in a poorly differentiated serous ovarian cancer. (x200
magnification).
4.3.4 Clinicopathological and molecular correlates of cyclin D1 protein
expression
High expression of cyclin D1 in tumour specimens was considered if>10% of cancer
cell nuclei stained positive for cyclin D1 protein. The pattern of nuclear staining was
uniform in the invasive tumour. Representative photomicrographs of tumour tissue
showing positive and negative staining for cyclin D1 are presented in Figure 4.4.
There was no correlation between the expression of cyclin D1 and volume of
residual disease (p=0.68), presence of ascites (p=0.49), stage (p=0.86), or tumour
grade (p=0.21)
There was no correlation between the expression of p53, p21Wafl/Cipl, pl6Ini:4a, cyclin
E, and pRb and nuclear accumulation of cyclin Dl. There was a significant
correlation between expression levels of cyclin Dl and p27Kipl as mentioned in
section 4.3. The results are shown in Table 4.6.
Table 4.6 Correlation between cyclin D1 expression and







Stage I 10 (8%) 1 (10%) 9
(n=134) II 4 (3%) 1 (25%) 3 0.86
III 102 (76%) 19 (19%) 83
IV 18 (13%) 4 (22%) 14
Grade 1 7 (5%) 0 (0%) 7
(n=134) 2 64 (48%) 10(16%) 54 0.21
3 63 (47%) 15 (23%) 48
Ascites No 45 (34%) 7 (16%) 38 0.49
(n=133) Yes 88 (66%) 18 (20%) 70
RD s 2 cm 103 (77%) 20(19%) 83 0.68









Positive > 10% 13 63 0.60
Negative s 10% 12 46
p21 wari/cipi (n_i34)
Positive > 10% 4 27 0.43
Negative £ 10% 21 82
p27Kip1 (n=134)
Positive > 65% 4 42 0.03
Negative s 65% 21 67
p1glnk4a (n=134)
Positive > 15% 9 55 0.19
Negative js 15% 16 54
Cyclin E (n=134)
Positive > 10% 12 68 0.18
Negative s 10% 13 41
pRb (n=134)
Positive > 20% 20 80 0.49
Negative s 20% 5 29
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Figure 4.4 (A) cyclin D1 positive tumour nuclei in a poorly differentiated
serous ovarian cancer. Insert represents nuclear staining at x400
magnification. (B) cyclin D1 negative tumour nuclei in a poorly
differentiated serous ovarian cancer. (x200 magnification).
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4.3.5 Clinicopathological and molecular correlates of cyclin E protein
expression
High expression of cyclin E in tumour specimens was considered if >10% of cancer
nuclei stained positive for cyclin E protein. The pattern of nuclear staining was
uniform and intense in the invasive tumour. Representative photomicrographs of
tumour tissue showing positive and negative staining for cyclin E are presented in
Figure 4.5. Expression of cyclin E correlated weakly to grade (p=0.03), with 14%
of well differentiated tumours staining positive for cyclin E, increasing to 59% and
65% in the moderately and poorly differentiated group respectively. There was no
correlation with volume of residual disease (p=0.53), presence of ascites (p=0.73) or
with stage (p=0.45)
There was no correlation between the expression of p21WafI/Cipl, p27Kipl, pl6Ink4a,
cyclin Dl, and pRb and nuclear accumulation of cyclin E. There was a significant
positive correlation between expression levels of cyclin E and p53 as mentioned in
section 4.3.1. These associations are demonstrated in Table 4.7.
Table 4.7 Correlation between cyclin E expression and clinicopathological
and molecular parameters
cyclin E (n=134)
Number Positive Negative p-value
>10% <10%
Stage I 10 (8%) 7 (70%) 3
(n=134) II 4 (3%) 1 (25%) 3 0.45
III 102 (76%) 62 (60%) 40
IV 18 (13%) 10 (55%) 8
Grade 1 7 (5%) 1 (14%) 6
(n=134) 2 64 (48%) 38 (59%) 26 0.03
3 63 (47%) 41 (65%) 22
Ascites No 45 (34%) 28 (62%) 17 0.73
(n=133) Yes 88 (66%) 52 (59%) 36
RD < 2 cm 103 (77%) 60 (58%) 43 0.53









Positive > 10% 51 25 0.045
Negative < 10% 29 29
P21 wafi/cipi (n—134)
Positive > 10% 16 15 0.29
Negative < 10% 64 39
p27Kip1 (n=134)
Positive > 65% 30 16 0.34
Negative < 65% 50 38
p16lnk4a (n=134)
Positive > 15% 41 23 0.33
Negative < 15% 39 31
cyclinDI (n=134)
Positive > 10% 12 13 0.18
Negative < 10% 68 41
pRb (n=134)
Positive > 20% 58 42 0.49
Negative < 20% 22 12
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Figure 4.5 (A) Marked overexpression of cyclin E in a well to moderately
differentiated serous ovarian cancer. Insert represents area at x400
magnification (B) Absence of cyclin E expression in a poorly differentiated
serous ovarian cancer. (x200 magnification).
4.3.6 Clinicopathological and molecular correlates of pRb protein
expression
Accumulation of pRb in tumour specimens was considered if >20% of cancer cell
nuclei stained positive for pRb protein. The pattern of nuclear staining was intense
and homogenous in the invasive tumour. Positive and negative immunohistochemical
staining of pRb in tumour tissue is demonstrated in Figure 4.6. Expression of pRb
did not correlate with the clinical parameters of stage (p=0.39), grade (p=0.17),
volume of residual disease (p=0.18) or presence of ascites (p=0.29).
There was no correlation between the expression of p2lWafl/Cipl; p27Kipl, cyclin Dl,
cyclin E, and pl6Ink4a and nuclear accumulation of pRb.








Stage I 10 (90%) 9 (90%) l
(n=134) II 4 (50%) 2 (50%) 2 0.39
III 102 (78%) 80 (78%) 22
IV 18 (83%) 15 (83%) 3
Grade 1 7 (5%) 7 (100%) 0
(n=134) 2 64 (48%) 47 (73%) 17 0.17
3 63 (47%) 52 (82%) 11
Ascites No 45 (34%) 36 (80%) 9 0.29
(n=133) Yes 88 (66%) 63 (72%) 25
RD < 2 cm 103 (77%) 74 (70%) 29 0.18









Positive > 10% 56 20 0.77
Negative < 10% 44 14
p21Waf1/C.P1 (n=134)
Positive > 10% 21 10 0.31
Negative < 10% 79 24
p27Klp1 (n=134)
Positive > 65% 32 14 0.33
Negative < 65% 68 20
p16lnk4a (n=134)
Positive > 15% 46 18 0.48
Negative < 15% 54 16
cyclinDI (n=134)
Positive > 10% 20 5 0.49
Negative < 10% 80 29
cyclinE (n=134)
Positive > 10% 58 22 0.49
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Figure 4.6 (A) pRb positive tumour nuclei in a well differentiated serous
ovarian cancer. Insert represents area at x400 magnification. (B) pRb
negative tumour nuclei in a moderately differentiated serous ovarian cancer.
Arrow indicates pRb staining in lymphocytes surrounding tumour cells.
(x200 magnification).
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4.3.7 Clinicopathological and molecular correlates of p16lnk4a protein
expression
High accumulation of pl6Ink4a in tumour specimens was considered if >15% of cancer
cell nuclei stained positive for pl6Ink4a protein. The pattern of nuclear staining was
homogenous in the invasive tumour. Positive and negative immunohistochemical
staining of pl6Ink4a in tumour tissue is demonstrated in Figures 4.7. Expression of
pl6ink4a did not correlate with the clinical parameters of stage (p=0.28), grade
(p=0.27), volume of residual disease (p=0.46) or presence of ascites (p=0.54)
As mentioned previously there was a significant negative association between the
expression of p53 and pl6Ink4a (p=0.004). There was no correlation between the
expression of p21WafI/Cipl, p27Kipl, pRb, cyclin D1 and cyclin E, and nuclear
accumulation of pl6Ink4a. The results are shown in Table 4.9.
Table 4.9 Correlation between pl6lnk4a expression and clinicopathological
and molecular parameters
p16 nk4a (n=134)
Number Positive Negative p-value
>15% <15%
Stage I 10 (8%) 7 (70%) 3
(n=134) II 4 (3%) 3 (75%) 1 0.28
III 102 (76%) 47 (46%) 55
IV 18 (13%) 7 (39%) 11
Grade 1 7 (5%) 5 (71%) 2
(n=134) 2 64 (48%) 27 (42%) 37 0.27
3 63 (47%) 32 (51%) 31
Ascites No 45 (34%) 23 (51%) 22 0.54
(n=133) Yes 88 (66%) 48 (54%) 40
RD s 2 cm 103 (77%) 51 (50%) 52 0.46










Positive > 10% 28 48 0.004
Negative < 10% 36 22
p21Wa(1/C.P1 (n--|34)
Positive > 10% 16 15 0.62
Negative < 10% 48 55
p27Klp1 (n=134)
Positive > 65% 23 23 0.71
Negative < 65% 41 47
Cyclin D1 (n=134)
Positive > 10% 9 16 0.19
Negative < 10% 55 54
Cyclin E (n=134)
Positive > 10% 41 39 0.33
Negative < 10% 23 31
pRb (n=134)
Positive > 20% 46 54 0.48
Negative < 20% 18 16
Figure 4.7 (A) High pl6Ink4a expression in a poorly differentiated serous
ovarian cancer. Insert represents area at x400 magnification. (B) Absent
pjgink4a eXpression jn a poorly differentiated serous ovarian cancer. (x200
magnification). Arrows indicate stromal cells displaying expression of
n 1bInk4aanrl iiqpH hq intprrmi rnntrnl
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4.4 Association between cell cycle gene expression, disease-specific
survival and progression-free interval
On univariate Cox regression analysis, molecular markers predictive of reduced DSS
included, overexpression of p53 (p=0.02), loss of p2lWafl/Cipl (0.02), increased levels
of cyclin D1 (p=0.03) and reduced p27Kipl (0.05). Overexpression of p53 (0.004),
loss of p2iWafl/Cipl (p=0.01) and reduced p27Kipl expression (p=0.05) were also
predictive of a shorter PFI. Although, a significant association was demonstrated
between the expression of p2lWafl/Cipl and p53 (p=0.006), not all p53 negative
tumours demonstrated an increase in p2iWafl/Cipl levels. When various combinations
of p53 and p21Wafl/Cipi expression were analysed, patients whose tumours
demonstrated overexpression of p53, and loss of p2iWafl/Cipl had a significantly
shorter DSS and PFI than patients with other combinations of these two molecules
(p=0.0008 and p=0.0001 respectively). These data are shown in Table 4.10.Kaplan-
Meier curves and log-rank p-value of DSS and PFI stratified according to p53 and
p21WafI/cipl status are shown in Figures 4.8 and 4.9 respectively.
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Table 4.10 Univariate analysis of the relationships between aberrant cell cycle









<10% vs> 10% 1.62 1.05-2.50 0.02 1.76 1.20-2.61 0.004
p21 wafi/cipi expression
<10% vs > 10% 1.90 1.09-3.32 0.02 1.80 1.13-3.0 0.01
p27Kip1expression
<65% vs > 65% 1.60 1.0-2.56 0.05 1.52 1.0-2.30 0.05
p16,nk4aexpression
<15%vs> 15% 1.20 0.79-1.83 0.40 1.29 0.89-1.88 0.18
Cyclin D1 expression
<10%vs> 10% 1.72 1.06 - 2.78 0.03 1.39 0.88-2.21 0.14
Cyclin E expression
<10% vs > 10% 1.32 0.86 - 2.05 0.21 1.0 0.69-1.47 0.98
pRb expression
<20% vs > 20% 1.06 0.64-1.73 0.83 0.89 0.57-1.38 0.61
p53>10% and
p21Wa'i/cipi<-|o% 2.08 1.36-3.20 0.0008 2.10 1.43-3.09 0.0001
❖ Disease-specific survival was calculated from date of primary laparotomy to the date of
disease-specific death or date of last follow up.
* 5-year disease-free interval was calculated from the date of primary laparotomy to date
of first reccurrence. Progressive disease as defined as partial or no response to





























p21 Waf1/Cip1 > io%(31)
(p = 0.02)
p21Waf1/CiP1 < 1Q%(103)
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Figure 4.8 Disease-specific survival (DSS) of patients with ovarian cancer according to
p53 and p2lwafi/ciPi status. (Aj Kaplan-Meier curve of DSS according to p53
expression > 10% or < 10%. (B) Kaplan-Meier curve of DSS according to
p2iwafi/cipiexpression >10% or < 10%. (C) Kaplan-Meier curve of DSS
comparing patients with combined expression of the two antigens:
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p21 Waf1/Cip1 > 10%(31)
(p = 0.011) p21 Waf1/Cip1 < 0%(103)
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Figure 4.9 5-year progression-free interval (PFI) of patients with ovarian cancer according
to p53 an<lp2iwafi/cipi status. (A) Kaplan-Meier curve of PFI according to p53
expression > 10% or < 10%. (B) Kaplan-Meier curve of PFI according to
p2iwafi/ciP[expression >10% or < 10%. (C) Kaplan-Meier curve of PFI
comparing patients with combined expression of the two antigens:
(o) p53+(M0%)/p21wafl/cipi-(<10%), (x) all other combinations of p53 andp21Wafl/Cipl expression.
The staining pattern of p53 across the tumour specimens revealed a bimodal
distribution. p53 expression of <5% was observed in 53 (40%) patients, >50% in 55
(41%) patients with the remainder (19%) being equally distributed between 5-50%.
Only 2 (8%) patients that had p53 expression of>5% but <50% were alive at 5 years,
in contrast to 23 (43%) in whom p53 expression was <5% (p<0.0001). Interestingly,
5-year survival rates of patients with p53 expression >50% was closer to the latter
group, at 36%. A similar association between expression of p53 and PFI was also
demonstrated (p<0.0001). The distribution of p53 in the tumours cohort is shown in
Figure 4.10. Kaplan-Meier survival curves and log-rank p-value of DSS and PFI are













0 -h T n
10 20 30 40 50 6 0- 70 80
Percentage nuclei staining of p53
9 o 1 o o
Figure 4.10
This histogram illustrates the expression of p53 in serous epithelial ovarian
tumours. The x-axis represents the range of nuclear staining for p53 across
the tumour cohort in increments of 5%. The y-axis represents the
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Figure 4.11 Kaplan-Meier curve for 5-year DSS (A) and PFI (B)
according to p53 stratification. Patients were assigned
3 subgroups according to their percentage of p53
nuclear staining, (x) p53 < 5% (n=53 (40%)),
(•) p53>5%<50% (n=26 (19%)), (a)P53>50% (n=55 (41%))
4.5 Multivariate Analysis
The results of multivariate Cox-regression analyses for disease-specific survival and
progression-free interval are shown in Table 4.1 la and 4.1 lb. In this study, the age
of patients at the time of diagnosis and pre-operative serum CA125 levels were not
significant in determining disease outcome on univariate analysis and were
consequently not included in the multivariate models. In addition, tumour grade and
clinical stage were also not incorporated in the multivariate analysis. The number of
well differentiated tumours was small in this cohort, and no survival advantage for
moderately differentiated tumours could be demonstrated in comparison to the
poorly differentiated ones. Moreover, the expression of several molecular markers
were found to significantly co-segregate with degree of tumour differentiation in
particular p2lWafl/Cipl (p=0.006). Similarly, stage was not included either, due to the
relatively small number of FIGO stage I and II cancers. In addition, larger volume of
post-operative RD and presence of ascites was significantly associated with
advanced tumour stage (data not shown).
The volume of post-operative residual disease remained the most important
determinant of DSS and PFI. Cyclin D1 overexpression and a combination of p53
overexpression and loss of p21Wafl/c,pl were also independent predictors ofDSS, with
the latter retaining its independent role in determining PFI. The presence of ascites
and performance status of patients became insignificant in both multivariate models.
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Table 4.11a Multivariate Cox regression analysis of overall DSS of
patients with serous EOC.
Disease-specific survival I
Clinical Parameter Relative risk 95% confidence p-value
interval
Residual disease 2.91 1.68-5.03 0.0001
<2cm vs > 2cm
Performance Status 1.55 0.96-2.52 0.073
0 vs 1,2
Ascites 1.29 0.75 - 2.22 0.35
Presence vs Absent
p53>10% and p21 <10% 2.35 1.44-3.83 0.0006
cyclin D1 1.75 1.03-2.96 0.038
<10% vs 10%
Disease-specific survival was calculated from date of primary
laparotomy to the date of disease-specific death or date of last follow
up.
Table 4.11b Multivariate Cox regression analysis of 5-year PFI of
patients with serous EOC.
5-year Progression-free Interval
Clinical Parameter Relative risk 95% confidence
interval
p-value
Residual disease 2.76 1.64-4.64 0.0001
<2cm vs > 2cm
Performance Status 1.17 0.75-1.82 0.49
0 vs 1,2
Ascites 1.45 0.91 -2.30 0.12
Present vs Absent
p53>10% and p21<10% 2.20 1.44-3.37 0.0003
5-year progression-free interval was calculated from date of primary
laparotomy to the date of first relapse or progression.
Chapter Five Discussion
5.1 Introduction
Ovarian cancer is the leading cause of death from gynaecological malignancies in the
western world. The course of this disease is dependent upon the clinical
characteristics of the affected individuals and the pathological features of their
cancer. Due to the insidious nature of this disease, patients often present with late
stage cancer in whom prognosis is poor. Other clinicopathological prognosticators
of disease outcome include the degree of tumour differentiation, presence of ascitis,
performance status of patients and volume of residual disease. With an increasing
understanding of genetic events involved in the neoplastic process, clinicians and
scientists are hoping to add to the clinicopathological determinants of ovarian cancer
progression, by analysing molecular markers thought to be relevant in cancer
biology. In addition to allowing estimates of clinical outcome, the in-vivo molecular
snapshots will broaden our understanding of basic cancer biology and may guide
future treatment based on a particular subset of genetic alterations.
Cancer per se is thought to arise from the step-wise accumulation of genetic
alterations that result in uncontrolled cellular proliferation and loss of differentiated
functions. In epithelial ovarian cells these abnormalities mainly accumulate as a
consequence of rapidly dividing cells and possible DNA damage during ovulation.
Dysregulation of cell cycle control has been implicated in the pathogenesis of most
human cancers. A precise balance between cyclins and CDKI's is critical to Gi/S
phase transition, and abnormal expression of these molecules is observed frequently
in ovarian cancer. Since 1994, several studies have been published that evaluate the
impact of these molecular markers on the survival of ovarian cancer patients. Brief
summaries of findings from several of these reports are detailed in Tables 2.2 - 2.4.
However, despite the accumulating number of publications there remain problems in
interpreting these results into meaningful clinical information. These problems
include:
• Small sample size in many studies which limits statistical power and subgroup
analyses.
• The inclusion of several subtypes of epithelial ovarian cancers as a single entity
in the final analyses of overall and progression-free survival of patients, in the
majority of reports. Some reports even include ovarian tumours of low
malignant potential (borderline) in their overall analyses.
• Details of statistical analysis are often obscure, in particular why certain factors
were removed or excluded from multivariate models. In addition, only results
from univariate analyses are reported in a significant number of studies.
• Non-uniform patient and disease populations. A few but significant numbers of
studies have reported "valuable insights into ovarian tumour biology" by
evaluating the expression of candidate genes across benign, borderline and
invasive ovarian tumours as a progression model. There is, however, no
clinicopathological evidence to suggest that such a progression model is valid for
ovarian cancer, and to date no pre-invasive model for development of EOC has
been identified that is comparable to that reported in other cancers, such as
cervical (46) and colorectal cancer (127).
In the present study, the expression of genes critical to Gl/S phase transition were
examined in a series of one type of EOC, namely serous cystadenocarcinomas. The
genes selected for this study are important in two pathways (cyclin
Dl/CDK4/pl6Ink4a and cyclin E/CDK2/p27Kipl) which are influenced by p53 and
p21wafi/C'P1j and ultimately converge on pRb (see Figure 2.1). Dysregulation of these
pathways is implicated in the pathogenesis of several human cancers but has been
studied to a far lesser extent in ovarian cancer with conflicting results. Abnormal
expression of these genes was analysed in relation to tumour characteristics and
disease outcome. The cohort was selected from a consecutive series of patients
treated for serous EOC at a tertiary referral gynaecology oncology centre. This is
reflected in the higher proportion of advanced FIGO stage III/IV tumours, than in the
published literature (8). Nevertheless, examination of traditional clinicopathological
variables confirmed that the cohort behaves in accordance with published series of
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epithelial ovarian cancers with regard to disease-specific and progression-free
survival of patients (60-67).
5.2 p53 and p2iWa,1/clp1 expression in serous epithelial ovarian cancer
p53 is a transcriptional regulator that is activated by a wide range of cellular stresses,
and is involved in cell cycle regulation, apoptosis and angiogenesis (282). These
stresses include DNA damage, hypoxia and redox stress. Inactivation of this tumour
suppressor gene is implicated in tumourigenesis of several human cancers (283), and
accumulation ofmutated p53 is an adverse prognostic indicator in breast (284), lung
(285) and colorectal cancer (286). Gene mutations and/or overexpression of p53
have been detected in 30 - 80% of epithelial ovarian tumours (234, 241, 246, 254).
A significant association between p53 immunostaining and p53 gene mutation in
ovarian cancer has also been reported in a number of studies (234, 246, 287, 288) in
accordance with the view that most p53 mutations lead to stabilisation of the protein.
In the largest series published to date Wen et al., (1999), examined p53 gene
mutation and expression in 105 epithelial ovarian tumours. Eighty-two percent of
the 60 tumours displaying DNA sequence alterations were due to missense mutations
and accumulation of p53 protein was observed in 92% of these cancers. The
remainder included nonsense and frameshift mutations, 50% of which displayed p53
overexpression. A small number of false positives were also observed but
nevertheless, a strong association between p53 mutation and expression was reported
(234). While it is likely that direct sequencing is the most reliable method for
determining p53 mutations, immunohistochemistry offers a practical tool for
analysing p53 protein accumulation in clinical specimens.
In this study less than 5% nuclear accumulation of p53 was observed in 53
specimens, greater than 50% accumulation in 55 tumours with the remainder (n = 26)
demonstrating intermediate expression. No cytoplasmic staining of p53 was
observed in any tumour specimens. Less than 10% of patients with intermediate
expression of p53, i.e. between 5% and 50%, were alive at 5 years which was a
significantly poorer outcome than the other 2 groups. A similar association between
the pattern of p53 expression and progression-free interval was also demonstrated.
The reason for this is unclear, although there are a number of potential explanations
that require further investigations. It is possible that tumours overexpressing wild
type p53 may exhibit some degree of immunostaining for p53 protein. In normal
cells, p53 is present at extremely low levels because the protein is rapidly degraded
following synthesis (289, 290). Levels of p53 increase rapidly in response to cellular
stresses, and with dramatic decrease in degradation through post-translational
modifications, and added stability by its interactions with other intracellular proteins,
positive immunostaining may result (231, 236, 237). For example mdm-2 is a
regulator of the homeostatic and functional attributes of p53. In addition to being a
transcriptional target of p53, mdm-2 forms a complex with p53 that negatively
influences p53's transcriptional function in-vivo. Moreover, mdm-2 acts as a
nuclear-cytoplasmic shuttle of p53 and thereby playing a significant role in the mdm-
2 mediated degradation of p53 by the ubiquitin dependent system. Secondly, certain
types of p53 mutations may result in very high levels of p53 protein that may have
some residual activity in regulating cellular functions. For example, a few studies
have found a better response to chemotherapy in laryngeal and bladder cancers that
display marked overexpression of p53 (291, 292). Thirdly, p53 point mutations
resulting in a stop codon, frameshift or nonsense mutations may result in altered or
truncated proteins that are detected using routine sequence analysis but not detected
by immunohistochemistry (293). Ovarian tumours with p53 gene mutations
resulting in truncated proteins have been shown to develop distant metastases more
rapidly than tumours with missense or no mutations, and consequently survival in
these patients is significantly shorter (294). More comprehensive mutation and
functional studies are required to decipher the role of mutant and wt p53 in ovarian
carcinogenesis.
The prognostic value of p53 accumulation as a marker of poor outcome in ovarian
cancer is controversial. A few studies report p53 overexpression as an adverse
factor of clinical outcome in ovarian cancer (241-245, 295) whereas several have
failed to confirm such findings (246-248, 256). In addition, most studies reporting
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significant results in univariate analysis fail to demonstrate an independent role of
p53 overexpression in multivariate analysis, when adjusted for traditional
clinicopathological characteristics of disease outcome. In the study, p53
overexpression was found to be an independent marker of shorter disease-specific
and progression-free survival when considered with residual disease, presence of
ascites, performance status and cyclin D1 expression. However, the prognostic
power of p53 strengthened significantly when analysed in combination with
p21Wafi/Cipi expression.
Historically, the expression of p2lWafl/Cipl has been considered a surrogate marker of
p53 function. Levels of p2iWafl/Cipl are predominantly regulated at the transcription
level by p53-dependent mechanisms, although there is increasing evidence to suggest
p53-independent pathways of p2iWafl/Cipl induction also exist. For example, in
gastric adenocarcinomas TGF-betal may be involved in the activation of p21Wafl/Cipl,
whereas in prostate cancer androgens may directly activate transcription (298).
Altered degradation and interaction with other cellular molecules may also influence
levels of p21Wafl/CipI. Studies involving fibroblasts from p53 knock out mice (211)
and ovarian and breast cancer cell lines (296, 297) with p53 mutations, show that up-
regulation of p21Wan/Cipl can occur independent ofp53 status. In this present study,
a significant negative correlation was found between the expression of p2iWafl/Cipl
and p53 accumulation. p21Wafl/Cipl loss in the presence of p53 overexpression
occurred in 65 cancer specimens. However, there were other tumours (n=ll) that
demonstrated a concurrent increase in the expression of both p53 and p21Wafl/Cipl
suggesting that at least in these tumours, p53-independent mechanisms may exist that
upregulate p2iWafl/Cipl levels. These results are consistent with findings in other
studies of ovarian cancer (244, 258). The mechanisms of p53-independent
regulation of p2iWafl/Cipl in ovarian cancer is unclear and warrants further research.
To investigate further the relationship between p53 and p21Wafl/Cipl, the impact of
aberrant expression of these two molecules on clinical outcome of patients was
examined. A limited number of studies have examined the prognostic value of
p21Wafi/Cipi jn £qq an(j /or its association with p53 (244, 245, 255, 256). The role
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of p53 as a prognostic marker in our study has been discussed previously. For
p21Wan/Cipl, univariate analysis showed that loss of this protein in serous epithelial
ovarian cancers is significantly associated with poor survival and a shorter
progression-free interval. These results in part, support findings by other
investigators (244, 255), although this study reports for the first time an association
between aberrant p2iWafl/Cipl expression and a shorter interval to disease progression.
However, an independent role for p2iWafl/ClP1 in predicting disease outcome when
considered with other molecular and clinical variables was not found. This was
mainly due to the incorporation of p53 expression in multivariate models. Bivariate
analysis of survival with p53 alone showed that the significance of aberrant
p21Wafi/ciPi expression was not retained, which may suggest levels of p21Wafl/Cipl are
predominantly regulated by p53-dependent mechanisms in our cohort of serous
ovarian tumours. However, despite this and the negative correlation between the
expression of these two proteins in this study, the prognostic relevance of combining
p53 and p21Wan/ClP1 expression in predicting clinical outcome was analysed. It was
found that loss of p2iWafl/ClP1 in conjunction with p53 overexpression was a stronger
predictor of reduced survival and progression-free interval, than other combinations
of expression or the aberrant expression of either molecule alone. This would
suggest the expression of p2iWafl/ClP' is not simply a surrogate marker of p53
function, and in part supports our previous observations of possible p53-independent
mechanisms of p2iWafl/ClP1 induction. These results are consistent with findings in
one other study of ovarian cancer (244). Anttila et al., (1999) reported a significant
co-segregation between p53 and p2lWafl/Cipl in 305 tumours of ovarian origin, and
demonstrated increased power in predicting clinical outcome when combining the
abnormal expression of both molecules than either alone. However their tumour
cohort comprised 5 different subtypes of ovarian cancers with 53 being classified as
miscellaneous (244).
p21Wafl/Cipl is involved in growth arrest and terminal differentiation in different cell
types (203, 211). Accumulation of p2iWafl/ClP1 correlates with well differentiated
tumours of breast (298) and oral cancer (206). In agreement with these observations,
the results presented support a significant correlation of elevated p2iWafl/ClP1 protein
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in well differentiated serous ovarian tumours with marked loss of p2iWafl/ClP1
expression in moderately differentiated and poorly differentiated cancers. A
dramatic loss of p2iWafl/ClP1 expression was observed between grade I and II tumours
and a smaller difference between grade II and III cancers. However, in this study
there were relatively few well differentiated tumours and a larger series of serous
epithelial ovarian cancers will be required to confirm this result. The expression of
p21 Wafi/cipi ^ nQt correiate wlth other clinicopathological features of malignancy,
which is consistent with results from other studies in ovarian cancer (244, 245, 256)
5.3 pRb /cyclin D1 / p16lnk4a pathway in serous epithelial ovarian
cancer
Cyclin D1 is a positive regulator of Gi progression, and is a putative oncogene
whose aberrant expression has been implicated in the pathogenesis of several types
of cancer. Cyclin D1 overexpression with or without gene amplification has been
identified as an adverse prognostic biomarker in breast (299), tongue (261), lung
(264), pancreatic (265) and gall bladder cancers (300). Amplification or mutation of
the CCNDl gene, encoding cyclin Dl, is rarely observed in ovarian cancer, although
increased levels ofmRNA and protein overexpression have been reported to occur in
14-95% of invasive tumours (155, 156, 266, 267). External mitogenic signalling and
regulation by other proteins integral to cell cycle progression may account for this
overexpression. For example, activating protein-1 (AP-1) complexes bind to specific
DNA sequences in the regulatory motifs of mitogen-responsive genes, that includes
CCNDl, which leads to cellular proliferation after stimulation by external mitogens
such as EGF, TPA or oestrogen (301). In breast cancer, a significant association is
demonstrated between cyclin Dl expression and ffa-2, a member of the AP-1 family
of activating proteins (302). Recent evidence also suggests that levels of TGF-a and
EGFR are independent predictors of outcome in head and neck and oesophageal
cancers possibly mediated via increased expression of cyclin Dl (303).
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This is the first study to report an independent prognostic role of cyclin D1 in
determining disease-specific survival of patients with serous epithelial ovarian
cancer. Nineteen percent of tumours demonstrated >10% nuclear accumulation of
cyclin D1 which is consistent with other reports of cyclin D1 overexpression in
ovarian cancer (266). The 5-year survival rate of patients in cyclin D1 positive and
negative groups was 9% and 39% respectively. Interestingly, there was no apparent
difference in survival between the 2 groups at 24-month census. Overexpression of
cyclin D1 was not associated with a shorter progression-free interval which may
explain why no difference was observed in the disease-specific survival of patients at
24-months follow up as already mentioned. In addition, there was a trend towards
cyclin D1 nuclear overexpression with increasing grade of tumour although this did
not reach significance. Overexpression of cyclin D1 was absent in all well
differentiated tumours and present in 14% of moderately differentiated and 23% of
poorly differentiated tumours.
The role of cyclin D1 in ovarian cancer has not been extensively studied. Barbieri et
al., (1999) are the only authors to report a significant association between cyclin D1
expression and disease outcome in a small series of epithelial ovarian cancers (267).
In brief, the authors investigated the relationship of cyclin D1 overexpression at the
mRNA and protein level in a series of 55 benign adenomas, 12 borderline tumours
and 37 carcinomas (including 5 recurrences). Cyclin D1 mRNA expression was
evaluated using RT-PCR and protein expression by Western blotting. mRNA was
detected in 95% of ovarian carcinomas, with 44% exhibiting strong signal intensity.
This was also reflected at the protein level. The positive association between cyclin
D1 protein overexpression and mRNA overexpression is consistent with other
reports in pancreatic (304) and oesophageal tumours (304). Overall survival in the
32 patients with primary ovarian carcinoma investigated with regard to cyclin D1
mRNA overexpression (defined by strong signal intensity), was calculated using the
Kaplan-Meier method and log-rank test. However, only 24 of these patients were
included for analysis of progression-free survival. The reason for this is unclear.
Nevertheless, a significantly shorter progression-free interval was observed in those
patients overexpressing cyclin Dl. There was no difference in overall survival. The
95
authors also reported a significant association between cyclin D1 overexpression
with serous carcinomas and poorly differentiated tumours. In contrast to this latter
finding, earlier studies of cyclin D1 overexpression in ovarian cancer have reported a
significant co-segregation with well-differentiated tumours (155, 266, 268).
However, in these studies the number of cases investigated is small. In one study,
borderline tumours are included with invasive malignancies in the correlation tests
(268) and with the large diversity of subtypes of EOC's studied in the remainder, the
results are difficult to interpret. Nevertheless, a similar finding has been reported in
breast cancer (269). However, other studies have found that cyclin D1
overexpression can inhibit the differentiation of myoblasts (305), and intestinal
epithelial cells (306), thus raising the possibility that cyclin D1 overexpression may
play a role in the inhibition of tumour cell differentiation in some cell types. In this
study we observed a trend but not a significant co-segregation between cyclin D1
overexpression and tumour grade (likely due to the small number of well-
differentiated tumours), and a larger study may be warranted to further define the
role of cyclin D1 in tumour differentiation in ovarian cancer.
pl6Ink4a is a tumour suppressor gene implicated in the pathogenesis ofmany different
cancers. Its protein product plays a role in the cell cycle, cell senescence, anoikis,
integrin-mediated cell spreading and angiogenesis (225, 226). Within the Gi phase
of the cell cycle it acts predominantly by inhibiting cyclin D1/CDK4-6 complexes,
thereby preventing phosphorylation of pRb (223). Inactivation ofpl6Ink4a, mainly by
promoter methylation and homozygous deletions, is frequently observed in human
cancer and loss of pl6Ink4a is associated with poor clinical outcome in head and neck
(261) and oesophageal cancers (229). Although loss of heterozygosity is present in
30-40% of ovarian cancers, inactivating mutation of the remaining allele or promoter
methylation is rarely observed (307). In addition, there is no evidence to suggest that
aberrant expression of plb11*43 is associated with clinical outcome in this cancer
(153, 263). In this study, there was no association between aberrant pl6Ink4a
expression with clinicopathological features of malignancy or clinical outcome of
patients with serous epithelial ovarian tumours. The Ink4A/ARF locus located on
chromosome 9 also encodes for a tumour suppressor gene called pi4^ {pl9ARF in
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mice). Transcription of this gene is activated through various means including the
E2F family of transcription factors and the resultant protein product converges on the
p53 pathway. There is thought to be extensive cross talk between the pl6Ink4a / Rb
and the pl4ARF / p53 pathways. It is therefore possible that levels of pl6Ink4a and p53
may be partly dependent, and in this study there was noted to be a significant
negative correlation between the expression of pl6Ink4a and p53. Of those p53
positive tumours, 37% demonstrated positive pl6Ink4a expression, whereas in p53
negative tumours there was positive plb1^43 in 62% of tumours. Further research is
required to fully decipher the function and interactions of pl6Ink4a.
The Rb gene family encodes a group of related proteins that participate in several
aspects of cell cycle regulation and control of gene expression, pi07 and pi30 have
a 30-35% amino acid identity to pRb, that also interact with the E2F family of
transcription factors. An important characteristic that distinguishes this family of
related proteins is the cell cycle timing of their interactions. pRb acts predominately
in the Gi phase whereas pl07 and pl30 is thought to act mainly in the S and Go
phases respectively. However, the role of these Rb related proteins in the pl6/cyclin
D1/CDK4 control pathway is unclear and is presently being explored. Rb gene
mutation and loss of pRb have been described in a variety of tumours that include
gall bladder (180), breast (181), lung (182), and bladder cancers (308). Loss of pRb
in these tumours is predictive of poor clinical outcome and is associated with
advanced stage and increasing tumour grade. Phosphorylation and inactivation of
pRb by cyclin/CDK complexes in Gj allows the release of transcription factors that
are necessary for cellular progression into S phase, and hence this protein is of
paramount importance in cell cycle regulation. However, similar to pl6Ink4a, despite
frequent loss of heterozygosity, alterations of the remaining allele and loss of pRb in
ovarian cancer is rare. Studies using immunohistochemistry to detect pRb in ovarian
cancer have reported that 70-85% of tumours express pRb and that loss of this
protein in the small minority of cancer specimens does not appear to co-segregate
with clinicopathological features of malignancy (183, 274, 275). The findings
presented in this study support the results from previous studies. pRb was present in
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79% of tumour specimens and loss was not associated with clinical outcome of
patients or other clinicopathological features ofmalignancy.
5.4 p27Klp1 and cyclin E expression in ovarian cancer
A trend for low p27Kipl expression and poor tumour differentiation has been reported
in breast (221), colon (309, 310) and bladder carcinoma (311). In addition,
experiments involving p27Kipl deficient mice show multiorgan hyperplasia, loss of
terminal differentiation and tumourigenesis (215, 217). Further evidence for the role
of p27Kipl in cellular differentiation comes from studies involving human colon
cancer cell lines (312, 313). Overexpression of p27Kipl results in partial growth
inhibition in these cancer cell lines and markedly increases sensitivity to the
induction of cell differentiation (312). The current study is the first to report a
significant correlation between reduced levels of p27Kipl expression and increasing
tumour grade in epithelial ovarian cancer. Fifty-seven percent of well differentiated
tumours displayed increased levels of p27Kipl, in contrast to 42% of moderately
differentiated and 23% of poorly differentiated cancers. The number of studies
examining the expression of p27Kipl in ovarian cancer is limited (257, 259, 266, 314),
and the majority have been unable to support a role of p27Kipl in tumour
differentiation. The results of this study are consistent with one previous study that
demonstrated reduced expression of p27Kipl was significantly associated with
increasing grade in a panel of ovarian tumours (266). The expression of p27Kipl and
cyclin D1 was examined by immunohistochemistry in 79 ovarian tumours that
included 22 benign cystadenomas, 23 borderline tumours and 34 ovarian cancers. A
steady decline in the levels of p27Kipl and cyclin D1 were observed from benign to
malignant lesions. Of the 34 invasive EOC's, increased expression of p27Kjpl and
cyclin D1 appeared to significantly co-segregate with well differentiated tumours,
although no difference was observed between moderately and poorly differentiated
tumours (the result relating to cyclin D1 overexpression and tumour differentiation in
this study, is however contradictory to observations in this present cohort).
However, with the limited number of specimens and even smaller subgroups of
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tumours when stratified for the degree of tumour differentiation (grade 1 (n=17),
grade 2 (n=9) and grade 3 (n=8)) the results reported in this study need to be
interpreted with caution.
Cyclin E is a late G1 cyclin forming a complex with CDK2 and is a candidate for
controlling G1 to S phase transition. High levels of cyclin E correlate with
increasing tumour grade in breast (315) and laryngeal cancers (316), although low
expression of cyclin E has been observed to associate with increasing tumour grade
and lymph node invasion in bladder cancer (311, 317). It has also been shown to be
associated with high tumour cell proliferative index in laryngeal cancer, and in these
tumours, increased expression was predictive of poorer disease outcome (316). The
role of cyclin E in tumour differentiation, cellular proliferation and clinical outcome
in ovarian cancer has not been defined. Increased level of cyclin E was associated
with increasing tumour grade in our study. The biggest difference was observed
between well differentiated and moderately differentiated tumours although a larger
study incorporating more well differentiated tumours is required. Gene amplification
has been reported in 20% of ovarian tumours, with significantly higher levels of
RNA and protein expression (271, 272). In this study overexpression of cyclin E
was present in 68% of tumour specimens, which is consistent with the degree of
overexpression in other tumour subtypes (316, 318). There was no relationship
between the expression of cyclin E and clinical outcome in this current study which
supports the reported findings in other studies of ovarian cancer (271, 272).
p27KiP' gene mutation is rare in human cancer (319). Protein levels are mainly
regulated by ubiquitin-mediated proteosome degradation, which is targeted by cyclin
E/CDK2 phosphorylation of p27Kipl (320). Therefore it is likely that reduced p27Kipl
and high cyclin E expression may be associated with cancer progression and
unfavourable prognosis. This relationship of aberrant p27KipI and cyclin E
expression is associated with increasing tumour grade and mortality in breast (315)
and bladder cancer (311) and malignant lymphomas (321). In this current study,
reduced p27Kipl and high cyclin E expression were associated with increasing tumour
grade, although there was no significant correlation between expression of these two
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molecules. In addition, aberrant expression of p27Kipl but not cyclin E, was
associated with unfavourable prognosis of patients. Decreased expression of p27Kipl
alone has been identified as an adverse prognostic factor in many tumour types
including colon (221, 222), and prostate carcinoma (220). In ovarian cancer, only
one study has supported an independent prognostic role of p27Kipl in determining the
clinical outcome of patients (259). In that study 33 short-term survivors (<2 years)
had significantly reduced p27Kipl levels in comparison to 33 long-term survivors
(>5years). The study was limited to FIGO stage II and III tumours and patients
surviving between 2 and 5 years were excluded. Positive p27Kipl was considered if
>50% tumour nuclei stained positive. A further study of 185 patients reported a
trend (which did not reach significance) of reduced overall survival in a small
subgroup of patients (n=ll) whose ovarian tumours completed lacked p27Kipl
expression (257). Due to the small number of cases that lacked p27Kipl expression,
all further analyses was considered with p27Kipl expression of >50% as positive
staining, and subsequently no correlation to clinicopathological parameters or
clinical outcome was reported. In this current study it was observed that reduced
P27Kipl expression correlated with poor clinical outcome (shorter DSS and PFI) in
univariate analysis, which did not retain significance as an independent prognostic
factor when adjusted for other clinicopathological and molecular variables. There
are several possible explanations for this. Firstly, a significant correlation was
observed between p27Kipl and p2iWafl/ClP1 expression in tumour specimens. This
finding is consistent with reports from other studies in ovarian cancer (257).
p21Waf/C'pi inhibits Cyclin E/CDK2 complexes and consequently the phosphorylation
of p27Kipl that is necessary for its degradation by the ubiquitin pathway. Loss of
p2|Wafi/ciPi would therefore result in active cyclin E/CDK2 complexes and increased
degradation of p27Kipl. Furthermore, bivariate analysis of survival revealed that
aberrant expression of p27Kipl did not retain significance when considered with
p2] Wafl/cipi expression Secondly, the multivariate model also included cyclin Dl,
which was inversely correlated with p27Kipl expression in this study. These data are
consistent with results in other tumour subtypes (322), although in contrast to a
previous study in ovarian cancer demonstrating concurrent decrease of p27Kipl and
cyclin Dl expression in moderately and poorly differentiated tumours (266).
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Moreover, p27Kipl expression appears to be induced by increased levels of cyclin D1
in some mammary epithelial cell lines (323). Similarly, levels of cyclin D1 are
markedly reduced in embryonic fibroblasts lacking genes encoding for p27Kipl and
p21Wafi/Cipi^ an(j reintroduction of p27Kipl into these cells appears to restore levels of
cyclin D1 (324). The association of cyclin D1 overexpression and reduced levels of
P27Kipl in ovarian cancer may represent common independent genetic aberrations
that occur in this cancer. As mentioned previously, upregulation of cyclin D1 may
be the result of external mitogenic signalling, thereby minimising the effect of
p27Kipl regulation of cyclin D1 levels.
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5.5 Conclusions and Future Directions
Epithelial ovarian cancer is a heterogeneous disease, constituting several subtypes of
tumours that are pathologically distinct and that have subtle biological and clinical
differences. Many investigators have reported contradictory results regarding the
prognostic significance of abnormal expression of cell cycle regulatory genes in the
progression of ovarian cancer, possibly as a consequence of examining epithelial
ovarian tumours as a single entity, and generally in a small number of cases.
Therefore, careful analysis from large groups of specific subtypes ofEOC is required
to establish whether the pattern of gene expression co-segregates with clinical and
pathological features ofmalignancy and disease outcome in those epithelial tumours.
Dysregulation of cell cycle genes involved in Gi to S phase progression is implicated
in the pathogenesis of several types of cancers. p53, p21Wafl/Cipl and cyclin D1 have
been most extensively studied in ovarian cancer, although the results of associations
between aberrant gene expression and clinicopathological features of malignancy
and clinical outcome of patients is conflicting. Hence, the aim of this study was to
examine the expression of genes along selected pathways, namely cyclin
Dl/CDK4/pl6Ink4a and cyclin E/CDK2/p27Kipl, which are influenced by p53 and
p2jWafi/cipi^ ancj t]iat ultimately converge on pRb, in a series of one type of EOC,
serous cystadenocarcinomas. The results of aberrant gene expression were
correlated to clinicopathological features of serous ovarian cancer and clinical
outcome of patients. A further aim was to investigate the various relationships
between the protein molecules themselves, in as much as is possible by
immunohistochemistry. The major findings of this study are the following:
• This study defines for the first time a significant relationship between aberrant
expression of cyclin D1 and clinical outcome in ovarian cancer. Overexpression
of cyclin D1 appears to be independently predictive of shorter disease-specific
survival in serous epithelial ovarian cancer.
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• The results from earlier studies are confirmed regarding the prognostic
significance of aberrant p53 and p2lWafl/CipI expression in determining clinical
outcome in EOC. Although this is the first study to report a significantly shorter
progression-free interval in those patients with tumours displaying low
p21Wafi/cipi expression, this result was not sustained in multivariate analysis when
adjusted for other factors. In addition, it was defined that more prognostic
information could be gained by simultaneous assessment of p53 and p2iWafl/Cipl
than either molecule alone.
• A differential pattern of p53 expression was reported across serous epithelial
ovarian cancers, and tumours displaying moderate expression of p53, i.e.
between 5% and 50% appear to have a significantly worse outcome than those
with either absent (<5%) or high (>50%) p53 expression. Further p53 mutational
and functional studies are required to investigate the significance of this result.
• The study also demonstrates that dysregulation of several cell cycle genes that
include p53, p21Wafl/CipI, p27Kipl and cyclin E appear to be important in tumour
differentiation of serous EOC. Overexpression of p53, loss of p21Wafl/Cipl,
reduced levels of p27Kipl and overexpression of cyclin E all correlated to an
increased lack of differentiation of cells.
The possible interactions between the proteins in serous epithelial ovarian cancer
were also investigated in this study. Based on the associations between the
expression of proteins examined in this current study, a model of cell cycle
dysregulation was hypothesised that may account for increased cellular proliferation
and consequently poor outcome in serous ovarian cancer. A flow diagram
summarising the observations, and hence possible interactions of proteins in Gi, is
presented in Figure 5.1.
Approximately 60% of tumours in this study demonstrate overexpression of
presumably mutated p53 protein, which co-segregates significantly, with reduced
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levels of p21Wafl/Cipl Therefore, the mechanism for p2iWafl/ClP1 upregulation in
serous ovarian cancer, may predominantly rely on transcriptional activation by wild-
type p53, which is absent in almost two-thirds of this tumour cohort. Subsequent to
the loss of p2iWafl/Cipl, the inhibition on cyclin E/CDK2 complexes may be
diminished. Active cyclin E/CDK2 complexes phosphorylate p27Kipl that results in
increased degradation of this protein by the ubiquitin-proteosome pathway. It was
observed that reduced p27Kipl expression in 77% of tumour specimens positively
correlated with p21Wafl/Cipl expression but not cyclin E. Therefore, the increased
activation of cyclin E/CDK2 complexes, subsequent to reduced p27Kipl and
p21Wafl/Cipl levels, may facilitate increased phosphorylation of pRb that results in
increased cellular proliferation.
There is evidence to suggest that p2iWafl/ClP1 is involved in facilitating the formation
of the active cyclin D1/CDK4 complex rather than its inhibition. However, in this
study, the level of p2iWafl/ClP1 is reduced, although with increased expression of
cyclin D1 and reduction of p27Kipl (that is also involved, but to a much lesser degree
in inhibiting cyclin D1/CDK4 complexes), the involvement of p2iWafl/ClP1 in
facilitating the formation of cyclin D1/CDK4 may not be as important. Similarly,
with increased levels of cyclin Dl, the inhibitory role of plb1^43 on cyclin D1/CDK4
complexes may also be diminished. Therefore, the net result of this pathway is also
likely to be increased phosphorylation of pRb and consequently cellular
proliferation.
In summary, dysregulation of one or both pathways that converge on pRb is
frequently observed in this study of serous epithelial ovarian cancer, which is likely
to result in the rapid proliferation of cells. In addition, the aberrant expression of
several cell cycle genes studied, correlates with poor tumour differentiation, and in
conjunction with increased cellular proliferation, rapid disease progression and poor
clinical outcome in those affected individuals is likely.
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p53 mutation resulting in overexpression of mutated p53, leads to reduced levels of
p2i wati/cipi Consequently, the inhibition on cyclin E/CDK2 is reduced, which results
in increased phosphorylation and therefore degradation of p27Kip1, leading to further
activation of cyclin E/CDK2. Active cyclin E/CDK2 complexes phosphorylate pRb
that subsequently results in increased cellular proliferation. Increased cyclin D1 /CDK4
complexes as a result of increased cyclin D1, also phosphorylates pRb and drives
cellular proliferation. The inhibitory role of p16,nk4a may be diminished in its effect due
to elevated levels of cyclin D1
■I f observed changes in the expression of genes in our cohort of serous epithelial ovarian cancer
I Inhibition
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Based on the outcome data and the proposed model of the role of these genes in
ovarian cancer, the following areas are seen priorities for further research:
• To further evaluate the role of specific p53 genes mutations that may result in
different functional p53 proteins. These proteins may or may not be detected by
immunohistochemistry and may have different functional capacities that impact
on disease progression in ovarian cancer. Therefore, by correlating p53
immunostaining or simply the presence of gene mutations by sequence analyses
with clinical outcome in ovarian cancer, may not be an accurate test for its role as
a prognostic indicator of this disease.
• A larger study of serous epithelial ovarian cancers is required to confirm the
prognostic role of cyclin D1 in this disease. In addition, the mechanism of cyclin
D1 overexpression in ovarian cancer remains to be developed and further
investigations of upstream regulators of cyclin D1 is required.
• It is also necessary to evaluate the expression of these cell cycle regulatory genes
in large cohorts of other epithelial ovarian cancers that include mucinous,
endometrioid and clear cell carcinomas thereby allowing meaningful
comparisons of aberrant cell cycle regulation between these tumour types. A
major limitation in drawing clinical conclusions from the published literature in
ovarian cancer is that the results reported are often contradictory. This may due
to incorporation of many types of epithelial ovarian cancers for final analyses in
most studies.
In conclusion, this study confirms that dysregulation of cell cycle genes is common
in serous ovarian cancers and interactions between protein products are complex. In
addition, this study also provides further evidence that the aberrant expression of
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